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SUMMARY 
 
Prions are unprecedented infectious pathogens responsible for a group of neurodegenerative 
disorders termed prion diseases (PDs) or transmissible spongiform encephalopathies (TSEs). 
Among the most notable PDs belong the Creutzfeldt-Jakob disease (CJD) in humans, the 
bovine spongiform encephalopathie (BSE) in cattle and scrapie in sheep. PDs appear either as 
genetic, infectious or sporadic disorders. Prions destroy the brain while the body remains 
mainly unaffected. The basic principle of all PDs is the conversion of the normal prion protein 
(PrPC) into a misfolded aggregated form, termed scrapie form of PrP (PrPSc). According to the 
prion protein hypothesis it is believed that PrPSc, either in a monomeric or in an oligomeric or 
aggregated state, promotes the conversion of PrPC into PrPSc by a self-propagating 
mechanism. The molecular composition of PrPSc and how the conversion of PrPC into PrPSc 
leads to pathology is not clear. Moreover, all familiar prion diseases have mutations within 
the Prnp locus and ablation of Prnp in mice confers resistance to prions. 
The goal of my thesis was to establish a Fluorescence Resonance Energy Transfer (FRET)-
based high-throughput assay which enables the detection of PrPC and PrPSc. To achieve this 
aim, I first established an enzyme-linked sandwich immuno assay (ELISA) with our in-house 
anti-PrP POM antibody library. By using enzymatic digestion and denaturation steps, I was 
able to discriminate between PrPC and PrPSc. Results from in vitro experiments revealed an 
excellent performance criteria for high-throughput applications by calculating the Z’ factor. A 
detection limit of 40 ng/ml recombinant PrP spiked in PrP knock out brain homogenate was 
determined. The ELISA was used to detect PrPSc in prion-infected organotypic slice cultures. 
Three weeks post-inoculution, accumulated PrPSc could be detected in organotypic slice 
culture homogenates which corresponds to a limit of detection of 1 ng PrPSc/µg total protein. 
Next, we were interested whether one of the luminescent conjugated polymers (LCPs) is able 
to inhibit the accumulation of PrPSc in the prion-infected slices. We found that the 
accumulation of PrPSc was inhibited by the use of the LCP, Poly(thiophene-3-acetic acid) 
[PTAA], which also decreased the amount of PK-resistant material detected by ELISA. The 
obtained ELISA results were compared with two other prion assays, the scrapie cell assay 
(SCA) which measures prion infectivity and the misfolding protein assay (MPA), which 
measures the amount of PrPSc aggregates. I found a good correlation between these results 
which shows that the ELISA is suitable to detect PK-resistant PrPSc in organotypic tissue 
cultures. 
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In the second and main part of my thesis, I established various FRET-based immunoassays, 
either in a homogeneous or in a solid phase, which enabled the detection of PrPC and PrPSc 
from different biological samples. I tested several POM antibodies, coupled either to the 
donor fluorophore Europium (Eu) or to the acceptor fluorophore APC, as FRET tandem pairs. 
The antibody pair POM1Eu and POM2APC were identified as the best pair. With ths 
combination a limit of detection lower than 125 pg/ml was obtained for recombinant PrP in 
the homogeneous phase. In addition, depending on the use of the POM antibodies, wild type 
and mutant recombinant PrP, as well as monomeric and aggregated recombinant PrP, could 
be distinguished by the newly established FRET assay. The recombinant PrP FRET assay 
revealed excellent performance criteria for high-throughput applications.  
Next, I detected PrPC and PrPSc in either cell lysates or mouse brain homogenates. The 
detection limit of PrPC in murine neuroblastoma cell lysates spiked with PrP knock out cell 
lysate was 16 µg/ml of total protein concentration. Including a proteolysis and denaturation 
step, PrPSc was detected in prion-infected 22L brain homogenate with a sensitivity of 5.5 log 
TCID50 units/g, which is less sensitive compared to the scrapie cell assay (up to 8 log TCID50 
units/g).  
The FRET assay also allows the detection of PrPC on the surface of intact murine and human 
cells. Pharmacological, genetic and enzymatic manipulation of the PrPC cell surface 
expression without affecting cell viability was monitored with 500 cells/well in a 384-plate 
format. The assay performance was excellent for high-throughput applications as determined 
by calculating the Z’ factor.  
In the last part of my thesis I established a novel FRET assay for the endocytosis of the PrP. I 
determined a half-life time of about 30 min for PrPC at the surface of human cells. After 45 
min a steady state was reached of endocytosed and recycled PrPC. The various different 
endocytosis pathways of PrPC can be blocked pharmacologically without affecting cell 
viability and monitored by FRET. Using siRNA treatment, genes involved in PrPC 
endocytosis were investigated. Two genes, AP2M1 and Rab5a blocked the internalisation, 
whereas EHD1 induced the uptake of PrPC. 
 
Overall, I have established various FRET-based immunoassays which are extremely valuable 
in the characterisation of both PrP isoforms and are intensively utilized for different 
applications in prion biology. 
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ZUSAMMENFASSUNG 
 
Prionen sind einzigartige infektiöse Pathogene, die für eine Reihe von neurodegenerativen 
Erkrankungen, zusammengefasst als Prionerkrankungen (PD) oder transmissible spongiforme 
Encephalopathien (TSE), verantwortlich sind. Dazu gehören die Creutzfeldt-Jakob 
Erkrankung (CJD) im Menschen, die bovine spongiform Encephalopathien (BSE) im Rind 
und Scrapie im Schaf. PD haben entweder einen genetischen, infektiösen oder sporadischen 
Ursprung. In allen drei Fällen wird das Gehirn von den Prionen zerstört, wobei der übrige 
Körper nicht in Mitleidenschaft gezogen wird. Das grundlegende Prinzip in allen PD ist die 
Umwandlung des normalen Prion Proteins (PrPC) in eine Erkrankungs-assoziierte Form 
(PrPSc), die „Prion“ bezeichnet wird. Gemäss der Prion Protein Hypothese wird angenommen, 
dass PrPSc, entweder in einer monomeren oder aggregierten Form, die Umwandlung von PrPC 
zu PrPSc fördert und dadurch selbstreplizierend und infektiös wird. 
Das Ziel meiner Doktorarbeit war die Etablierung einer FRET-basierten Hochdurchsatz-
Methode, die die Detektion von PrPC und PrPSc ermöglicht. Als Voraussetung hierfür musste 
zuerst ein Enzym-gekoppelter Sandwich Immunoassay (ELISA) mit unseren eigenen anti-PrP 
POM Antikörpern etabliert werden. Durch eine enzymatische Verdauung und einen 
Denaturationsschritt war ich in der Lage, PrPC und PrPSc voneinander zu unterscheiden. 
Resultate von in vitro Experimenten zeigten eine exzellente Leistung für Hochdurchsatz-
Anwendungen durch die Berechnung des Z’ Faktors. Für rekombinantes PrP wurde eine 
Detektionslimite von 40 ng/ml bestimmt. PrPSc konnte in organotypischen zerebellären 
Gewebskulturen 19 Tage nach Inokulation bestimmt werden. Zusätzlich habe ich den PrPSc 
ELISA mit zwei anderen Prion Methoden verglichen und fand eine gute Korrelation zwischen 
den Resultaten. 
Im zweiten und Hauptteil meiner Doktorarbeit habe ich zahlreiche FRET-basierte 
Immunoassays entweder in der homogenen oder in der soliden Phase etabliert, die die 
Detektion von PrPC und PrPSc aus verschiedenen biologischen Proben ermöglichen. Dazu 
verwendete ich POM Antikörper, die entweder an das Donorfluorophor Europium oder an das 
Akzeptorfluorophor APC gekoppelt sind, als FRET Tandempaare. Eine Detektions-limite 
tiefer als 125 pg/ml wurde für rekombinantes PrP bestimmt. Kein FRET Signal wurde in PrP 
defizienten Zelllysaten detektiert. Zusätzlich, abhängig von der POM Anti-körper 
Kombination, konnten sowohl Wildtyp und Mutanten als auch monomeres und aggregiertes 
rekombinantes PrP unterschieden werden. Der neu etablierte FRET assay 
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ermöglicht ausserdem Bindungsstudien als auch enzymatische Manipulation von 
rekombinantem PrP. Der rekombinante PrP FRET Assay glänzt mit exzellenter Leistung für 
Hochdurchsatz Anwendungen. 
Im weiteren Verlauf habe ich PrPC und PrPSc entweder in Zelllysaten oder murinen 
Hirnhomogenaten detektiert. Die Detektionslimite für PrPC in N2a Zelllysaten ergab 16 
µg/ml. Durch einen enzymatischen Verdau und einen Denaturierungsschritt konnte ich PrPSc 
in Prion-infizierten 22L Hirnhomogenat bei einer Verdünnung von 10-5 nachweisen, was 
weniger sensitiv ist verglichen mit dem Scrapie Cell Assay (bis zu 10-9). 
Der FRET Assay erlaubt ausserdem die Detektion von PrPC auf intakten murinen und 
humanen Zellen. Pharmakologische, genetische und enzymatische Manipulation der PrPC 
Zelloberflächenexpression, die die Zellviabilität nicht beieinflussen, wurden mit 500 
Zellen/ml im 384-Plattenformat durchgeführt. Die FRET Assay Leistung war hervorragend 
und ermöglicht Hochdurchsatz-Anwendungen. 
Im letzten Teil meiner Doktorarbeit habe ich einen neuen und sehr cleveren FRET assay 
etabliert, der die Endocytose von PrP misst. Dabei habe ich eine Halbwertszeit der PrPC 
Zelloberflächen-Expression von 30 min bestimmt. Nach 45 min hat sich ein Gleichgewicht 
eingestellt von endozytierten und recyclenden PrPC. Die verschiedenen Endozytose Wege von 
PrPC wurden pharmakologisch blockiert, ohne die Zellviabilität zu beeinträchtigen. Mittels 
siRNA Behandlung wurden Gene identifiziert, die an der Endozytose von PrPC beteiligt sind. 
Zwei Gene, AP2M1 und Rab5a blockieren die Endocytose, während EHD1 die 
Internalisierung von PrPC induziert. 
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PRION GLOSSARY 
 
Prion: Agent of transmissible spongiform encephalopathy (TSE), with unconventional 
properties. The term does not have structural implications other than that a protein is an 
essential component. 
 
‘Protein-only’ hypothesis: Maintains, that the prion is devoid of informational nucleic acid, 
and that the essential pathogenic component is protein (or glycoprotein). Gentic evidence 
indicates that the protein is an abnormal form of PrP (perhaps identical with PrPSc). The 
association with other ‘non-informational’ molecules (such as glycosaminoglycans, or maybe 
even short nucleic acids) is not excluded. 
 
PrPC: the naturally occurring form of the mature Prnp gene product. Its presence in a given 
cell type is necessary, but not sufficient, for replication of the prion. 
 
PrPSc: An ‘abnormal’ form of the mature Prnp gene product found in tissue of TSE sufferers, 
defined as being partly resistant to digestion by proteinase K (PK) under standardized 
conditions. It is believed to differ from PrPC only (or mainly) conformationally, and is often 
considered to be the transmissible agent or prion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Aguzzi and Weissmann (Aguzzi and Weissmann, 1997) 
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ABBREVIATIONS 
 
2Eu    POM2 antibody coupled to Europium (Eu) 
2APC    POM2 antibody coupled to Allophycocyanin (APC) 
2Eu/APC   POM2 Europium/APC FRET antibody pair 
%CV    Coefficient of variation 
APC    Allophycocyanin 
BFA    Brefeldin A 
BH    Brain homogenate 
BSE    Bovine spongiform encephalopathy 
CJD    Creutzfeldt-Jakob disease 
CNS    Central nervous system 
COCSBH   Cultured organotypic cerebellar slice brain homogenate 
CPZ    Chlorpromazine 
CWD    Chronic wasting disease 
DPI    Days post-inoculation 
DIV    Days in vitro 
Eu    Europium 
FFI    Fatal familial insomnia 
FRET    Förster/Fluorescence resonance energy transfer 
GdnSCN    Guanidinium thiocyanate  
GPI    Glycosylphosphatidylinositol 
GSS    Gerstmann-Sträussler-Scheinker disease 
HTRF    Homogeneous time-resolved fluorescence 
KO    Knockout 
LOD    Limit of detection 
MβCD    Methyl-β-cyclodextrine 
OHSCs   Organotypic hippocampal slice cultures 
PD    Prion diseases 
PI-PLC   Phosphoinositide phosholipase C 
PK    Proteinase K 
PMSF    Phenylmethylsulfonyl fluoride 
POSCA   Prion organotypic slice culture assay 
PRNP    Prion protein gene 
PrPC    Cellular prion protein 
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PrPSc    Scrapie-associated prion protein 
PTAA    Poly(thiophene-3-acetic acid) 
RecPrP   Recombinant prion protein 
RML    Rocky Mountain laboratory strain 
SCA    Scrapie cell assay 
SCEPA   Scrapie cell assay in end point format 
TR    Time-resolved 
TSE    Transmissible spongiform encephalopathy 
vCJD    Variant Creutzfeldt-Jakob disease  
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INTRODUCTION 
 
History of Prion Diseases (PDs) and Research 
 
The existence of prions is known in one or the other form for more than three centuries. The 
earliest written record describing ataxic illnesses was reported in the mid 18th century [Brown 
and Bradley 1998]. This PD killed entire flocks of sheep and was named scrapie. At that time, 
scrapie was already prevalent in central Europe and it was well known that this disease is 
transmissible. By isolating animals with scrapie from healthy stock, the spread was kept in 
check and the damage limited [Leopoldt, 1759]. Experimentally, 200 years later Stewart 
Stockman described that the incubation time for scrapie transmission takes two to three years 
[Aguzzi and Calella, 2009]. In the late nineteen thirties, accidental and experimental 
transmission of scrapie in sheep was reported [Cuille and Chelle 1939; Wilson et al. 1950]. 
The hypothesis that scrapie is caused by a filterable virus became widely held [Cuille and 
Chelle 1939; Wilson et al. 1950]. 
In the 1920s and 1930s, a high incidence of a rapidly progressive dementia was described in 
humans [Creutzfeldt, 1920; Jakob, 1921]. It was Creutzfeldt and Jacob nosological 
classification that lead to the eponym of this disease (Creutzfeldt-Jacob disease (CJD)) which 
has been maintained until nowadays. In the 1950s among the Fore people of New Guinea, an 
outbreak of Kuru occurred [Gajdusek and Zigas, 1957]. William Hadlow, an American 
veternarian pathologist recognised similar lesions in Kuru and scrapie and he hypothesised a 
link between both diseases [Hadlow, 1959]. A crucial turning point in the field of prions were 
the mid 1960s, when Carleton Gajdusek and collegues found the transmissible nature of a 
small-sized infectious agent by experimental transmission of Kuru and CJD to chimpanzees 
[Gajdusek et al., 1966; Gibbs et al., 1968]. Unfortunately, transmission of infectivity was also 
proven in humans many years later. Dozens of people had died from CJD after having been 
infected by prion-infected surgical instruments or after having received contaminated growth 
hormone injections [Duffy et al., 1974]. Like Hadlow, Igor Klatzo made a similar intellectual 
leap between kuru and CJD [Klatzo et al., 1959]. At that time, speculations to the nature of the 
scrapie agent ranged from DNA viruses to membrane fragments to polysaccharides to 
proteins. 
In 1966/7, the findings of Tikvah Alper that the scrapie agent resists to DNA elimination by 
ultraviolet and ionising irradiation, and therefore disproved the involvement of a virus in the 
pathological process [Alper et al., 1966; Alper et al., 1967]. The protein-only hypothesis was 
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proposed by the mathematician J.S. Griffith [Griffith 1967]. It states that under certain 
circumstances proteins might be able to self-replicate and misfold. Patricia Merz discovered 
scrapie-associated fibrils in all TSEs by EM images [Merz et al., 1983].  
The absence of a conventional microorganism responsible for this group of rare 
neurodegenerative conditions of unknown etiology remained curious throughout the first 
description. However, PDs remained ill-defined. This may explain the large number of names 
given to this neurological disorder. CJD, kuru and scrapie are now referred to as prion 
diseases. 
The arduous scientific odyssey in understanding PDs ended up in 1982 as Stanley B. Prusiner 
coined the term “prion”, a PROteinaceous INfectious particle that lack nucleic acids longer 
than 50 bases. This hypothesis known as the “protein-only hypothesis” defines the prion 
problem as one of protein structure. The prion concept readily explains how a disease can be 
manifested as a heritable as well as an infectious illness [Prusiner SB, 1982]. 
This theory led to a better understanding of the unknown mechanism of prion diseases, 
including CJD, scrapie and BSE. In 1985, the gene encoding the PrP was identified [Oesch et 
al., 1985]. Scientists discovered that uninfected people produce a normal form of the PrP 
protein [Basler et al., 1986]. Shortly afterwards, the first mutation in PRNP was linked to 
familial PDs [Hsiao et al., 1989] and PrP transgenic mice with the same mutation developed 
neurodegeneration. Mice lacking PrP (PrP-/-) are resistant to prion infection [Büeler et al., 
1993; Sailer et al., 1994]. Essential findings in prion research for the last 20 years are 
summarized in Table 1.  
1994 Cell-free conversion of PrPC to protease-resistant PrP [Kocisko et al., 1994] 
1996 First NMR structure of murine PrPC [Riek et al., 1996] 
  New variant of CJD (nvCJD) identified [Will et al., 1996] 
  BSE prion strain carries a distinct glycotype signature [Collinge et al., 1996] 
1997 Evidence that nvCJD is caused by the BSE agent [Bruce et al., 1997; Hill et al., 1997] 
  B-lymphocytes are necessary for peripheral prion pathogenesis [Klein et al., 1997] 
1998 Genes controlling incubation period are congruent with Prnp [Moore et al., 1998]  
1999 Discovery of Doppel, the PrPC homolog [Moore et al., 1999] 
2000 Temporary depletion of lymphoid FDCs impairs prion replication [Montrasio et al., 2000] 
2001 Complement involved in prion pathogenesis [Klein et al., 2001; Mabbott et al., 2001] 
2003 Transgenic expression of soluble PrP inhibits prion replication [Meier et al., 2003] 
2004 Intracerebral inoculation of fibrils consisting of recMoPrP(89-230) produced a transmissible neurologic 
disease with protease-resistant PrP [Legname et al., 2004]  
2005 In vitro generation of infectious scrapie prions [Castilla et al., 2005] 
2006 Production of cattle lacking prion protein [Richt et al., 2006] 
2007 Formation of native prions from minimal components in vitro [Deleault et al., 2007] 
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2008 A versatile prion replication assay in organotypic brain slices [Falsig et al., 2008] 
2009 PrPC mediates impairment of synaptic plasticity by amyloid-beta oligomers [Laurén et al., 2009] 
2010 Darwinian evolution of prions in cell culture [Li et al., 2010] 
2011 Rapid cell-surface prion protein conversion revealed using a novel cell system [Goold et al., 2011] 
2012 Human prion protein binds Argonaute and promotes accumulation of microRNA effector complexes 
[Gibbings et al., 2012] 
2013 The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein [Sonati et al., 
2013] 
 
Prion Diseases  
 
Prions, the infectious agents of PDs, inexorably perforate the brain. Before the onset of clinical 
symptoms, these diseases have incubation times of more than 30 years in humans [Alpers et 
al., 1979] and are characterized by a myriad of small vacuoles producing a sponge-like 
appearance and by astrocytic gliosis in microscopic examinations of the CNS [Zlotnik and 
Stamp, 1961]. The degree of spongiform degeneration is quite variable and it is believed to be 
due to prion strains and genetic background, whereas the gliosis correlates well with the 
degree of neuronal loss [Masters and Richardson Jr, 1978]. So far, sixteen different variants of 
PDs, also known as transmissible spongiform encephalo-pathies (TSEs), have been reported: 9 
in humans and 7 in animals [Liberski, 2012]. The most prominent members of PDs in humans 
are variant and classical Creutzfeldt-Jakob disease (CJD) [Gibbs et al. 1968] and Kuru 
[Gajdusek et al., 1966]. A wide range of animal species are affected by TSEs (i.e. sheep and 
goat [Cuille and Chelle, 1939], deer and elk [Wiliams and Young, 1980] and cattle [Hope et 
al., 1989]). 
The origin of PDs can be classified as either inherited, acquired or as sporadic if a genetic or 
infectious cause can be excluded. Another pathological hallmark of PDs is associated with 
accumulation of prions, aggregated PrPSc, the misfolded isoform of host-encoded cellular 
prion protein (PrPC) [Prusiner et al., 1981; Prusiner et al., 1984]. Prions are inimitable in that 
they defy all conventional methods which routinely and reliably deactivate all known bacteria 
and viruses [Gordon, 1946, Gibbs jr et al., 1978]. Furthermore, prions lack their own genetic 
information [Alper et al., 1967].  
Although prion diseases share certain morphological and pathophysiological features similar 
to other progressive neuropathologies (e.g. Alzheimer´s (AD) and Parkinson´s disease) they 
were considered for a long time as unique in that prions are transmissible [Prusiner, 2012]. 
This view had to be revised recently by the identification of self-propagating Aβ 
                                                                                                       INTRODUCTION 
___________________________________________________________________________ 
 14 
conformations in AD which spread by cell-to-cell transmission like prions [Stöhr et al., 2012], 
transmission of pathological α-synclein initiating Parkinson-like neurodegeneration in 
nontransgenic mice [Luk et al., 2012], or a prion-like infectious cycle of serum amyloid A 
[Westermark and Westermark, 2010]. 
 
Prion Diseases in Animals  
 
PDs in animals mostly occur as infectious disorders. Neuropathological signs are spongiform 
vacuolation, astrogliosis and the deposition of PrPSc in the CNS forming amyloid plaques 
[Aguzzi, 2006]. Naturally occurring scrapie is the ancient and prototypic form of PDs and has 
been documented in sheep since 1732 [McGowan, 1922]. Scrapie usually affects animals 
between the ages of 2 and 5 years and the incubation time varies between 1 to 2 years and is 
accompanied by behavioural changes, blindness and ataxia [Dickinson, 1976]. Death occurs 
within a few weeks to 6 months after diagnosis [Aguzzi and Calella, 2009]. Various clinico-
pathological phenotypes have been seen which may be due to polymorphisms in sheep PrP. 
Scrapie is not infectious for humans and no link has been found between CJD [Chatelain et al., 
1981]. 
Chronic wasting disease (CWD) is a TSE in free-ranging captive and occurs predominantly in 
the US and Canada [Sigurdson & Aguzzi, 2007]. The affected species include deer, elk and 
moose. The origin of CWD is still unknown. Intracerebral transmission of the scrapie agent 
induces CWD in elk. CWD is experimentally transmissible to cattle, sheep, goats and other 
animals. Until now, natural transmission of CWD has not been evident in humans.  
It happened in 1986, as the outbreak of an unknown brain disease in cattle shocked Europe 
[Wilesmith et al., 1988] and became popular in vernacular language as “mad cow” disease or 
bovine spongiform encephalopathy (BSE). At culmination in 1992, nearly 1’000 cattle were 
affected weekly [see the BSE Portal on the World Organisation for Animal Health website]. 
The only way to eradicate the excessive spread ended up in slaughtering of 3.7 mio cattle. The 
likely cause of the BSE epidemic was considered in meat and bone meal contaminated 
withinfectious prions. A ban of meat and bone meal in ruminants feed ultimately resulted in a 
decline of the epidemic [Ducrot C, 2008], although sporadically BSE cases still occur. But that 
was not all, BSE has also been transmitted by contaminated meat to humans in the form of a 
new variation of Creutzfeldt-Jacob disease (vCJD) [Bruce ME, 1997], which led to 300 
victims, mostly in the UK. The origin of BSE is unknown. Natural transmission of BSE to 
goats and sheep has been reported. 
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Several other widespread occurrences in TSEs have been observed in other wild or 
domesticated species of animals, such as cats, mink [Marsh and Hadlow, 1992] and lemurs.  
 
Prion Diseases in Humans 
 
Sporadic Creutzfeldt-Jacob disease (sCJD) is the most frequent human prion disease, which 
accounts for roughly 85% of all CJD cases [Aguzzi and Callela, 2009]. It also includes fatal 
insomnia and variably protease-sensitive prionopathy. The annual incidence is 1-2 
cases/million population equally distributed in both sexes with a clinical onset between 55 and 
75 years [Brown et al., 1986]. Although different variants of sCJD have been classified, at 
terminal stage most patients become unresponsive to exterior stimuli due to rapid progressive 
dementia [Rabinovici et al., 2006]. Neuropathological hallmarks are the presence of 
spongiform changes and sparse PrPSc-containing plaques in the CNS [Gambetti et al., 2003]. 
The etiology of sCJD is unknown. Several hypotheses propose that sCJD is caused by somatic 
mutations in the prion protein gene (Prnp) [Gajdusek, 1977] or suggest that spontaneous 
conversion of normal PrPC into disease-associated PrPSc may be the trigger of the disease 
[Prusiner, 1989]. Polymorphisms in the Prnp (i.e. M129V) have been associated with a 
predisposition to the development of sporadic CJD [Collinge et al., 1991].  
Genetic PDs are caused by autosomal, dominantly inherited mutations in the prion protein 
gene (Prnp) [Cohen & Prusiner, 1998]. Several different genetic PDs are classified according 
to clinical symptoms, although all of them result from mutations in PRNP, including familial 
(f) CJD, Gerstmann-Sträussler-Scheinker syndrome (GSS) [Gajdusek, 1977] and fatal familial 
insomnia (FFI) [Medori et al., 1992]. The onset of disease is much earlier though, starting 
between 30 and 60 years of age. Aquired or transmissible human PDs, which account for only 
5% of all human TSEs, have been first discovered in the 1920’s in Fore people of Papua New 
Guinea. Among the Fore people a ritualistic practice was to eat the brain of dead relatives, an 
attempt to become immortal [Glasse 1967]. The disease was named as Kuru. At its peak, the 
epidemic killed 1-2% of the population. After banning these rituals the epidemic declined. 
Pretty soon scientists proved that the etiology of Kuru is the consumption of brain; it is also 
transmissible to chimpanzees [Gajdusek et al. 1966]. Acquired PDs were next discovered in 
the mid 1970’s when hundreds of young people died of spongiform encephalopathy after 
receiving prion-tainted growth hormones extracted from human corpses [Koch et al., 1985], 
neurosurgical instruments [Duffy et al., 1974] or dura mater grafts [Thadani et al., 1988]. The 
latest finding was in the 1990’s, the new variant (v) form of CJD which resulted from prions 
being transmitted from cattle with BSE to humans via consumption of meat products, 
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especially the brain [Chazot et al. 1996]. vCJD was shown to be transmitted through blood 
[Llewelyn et al., 2004]. 
The Cellular Prion Protein (PrPC) 
 
The Prion Protein (PrP) is 253 amino acid (aa) in length and encoded by the chromosomal 
prion protein gene, denoted Prnp. Prnp belongs to the Prn gene family which also encodes 
Prnd, the doppel protein [Moore et al., 1999] and Sprn, the shadoo protein [Watts and 
Westaway, 2007]. All studied PrP genes from various species comprise three exons. The PrP 
open reading frame ORF is located within one exon. The other two exons contain promoter 
and termination sites [Basler et al., 1986]. Interestingly, the sequence from more than 45 PrP 
genes studied so far shows a high degree of conservation, assuming an important function of 
PrP through evolution [Wopfner et al., 1999]. 
Like other membrane-resident proteins, PrP is synthesized in the rough endoplasmatic 
reticulum and travels through the Golgi apparatus to the cell surface [Harris, 1999]. During its 
biosynthetic maturation, PrPC becomes post-translationally modified, including cleavage of 
the first 22 amino (N)-terminal signal peptide, addition of N-linked oligosaccharide chains, 
formation of a disulfide bond and attachment of a GPI anchor (removing of the last 23 C-
terminal aa) which promotes its localisation in lipid rafts. PrPC contains about 45% α-helix 
[Pan, 1993] and two short stretches of β-sheet [Riek et al. 1996]. PrPC has two potential sites 
for glycosylation (asparagines 181 and 197 in mouse PrPC) whose differential occupancy 
results in four different subpopulations of PrPC: unglycosylated PrPC, monoglycosylated PrP 
at N181, monoglycosylated PrP at N197 and diglycosylated PrPC [Haraguchi et al., 1989]. All 
of these PrPC subtypes can be distinguished by Western blotting, because of their distinct 
molecular weight. 
The normal PrPC is a highly conserved protein that has been identified in all mammals and 
birds so far, as well as in the frog Xenopus laevis [Strumbo et al. 2001], and in fish [Oidtmann 
et al. 2003; Rivera-Mila et al. 2003]. PrPC is normally expressed at the surface of neurons, 
various non-neuronal tissues and leukocytes [Aguzzi and Polymenidou, 2004] and attached by 
a glycolipid moiety [Stahl et al. 1987].  
The long N-terminal part (approximately 100 aa) of PrPC appears to be unstructured according 
to in vitro NMR studies performed with murine recombinant PrP [Hornemann et al., 1997; 
Riek et al., 1997]. In vivo, PrPC may be part of a protein complex, in which some yet 
unidentified proteins could serve as chaperones facilitating the folding and function of PrP. 
The N-terminal part of PrP contains a tandem repeat of an octapeptide repeat.  
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In contrast to the N-terminus of PrP, the carboxy terminus has a defined structure, which has 
been extensively analysed [Riek et al., 1996; Wuthrich and Riek, 2001] and was found to 
consist of two small β-sheets and three longer α-helices, connected by four loops. Another 
interesting element of PrP is the highly hydrophobic region that lies between the unstructured 
and the structured part of PrP. This hydrophobic domain is believed to play an important 
functional role. Transgenic animals expressing N-terminal deletions of aa 45-121 or 45-134 
(but not shorter deleations) confers strong neurotoxicity to PrP in vivo. This effect is abrogated 
by (re-) indroducing WT PrPC [Shmerling et al., 1998]. 
Although much has been published and speculated, the function of PrPC is still a conundrum. 
Definately, PDs cannot propagate in animals devoid of the PRNP gene [Sailer et al., 1994]. 
However, PrPC`s conserved expression in different species infers some relevance in the basic 
physiological processes. PrPC has been proposed to be involved in several functions: copper 
and/or zinc ion transport or metabolism [Pauly and Harris, 1998; Watt and Hooper, 2003; 
Brown, 2001], protection from oxidative stress [Brown, 2001], cellular signalling [Chiarini, 
2002; Mouillet-Richard, 2000], membrane excitability and synaptic transmission [Mallucci, 
2002; Collinge, 1994], neuritogenesis [Graner, 2000] and apoptosis [Chiarini, 2002; Solforosi, 
2004]. These functions could be achieved by interaction of PrPC with different binding 
partners [Gauczynski, 2001], such as laminin [Rieger, 1997] or the chaperone BiP [Jin, 2000]. 
A recent publication by Bremer and co-worker showed that neuronal PrPC and its regulated 
proteolysis are required to maintan peripheral myelination [Bremer, 2010].  
 
PrPC Internalization 
 
GPI-anchored proteins (GPI-AP) are an amalgamation of proteins, carbohydrates and lipids. 
They are organized in specialized membrane domains or “rafts” at the cell surface. GPI-APs 
are involved in a range of physiological diseases and thus, endocytosis has been intensively 
debated. A prominent member of GPI-AP is the cellular prion protein (PrPC). PrPC is 
constitutively endocytosed in vitro [Harris 2003; Prado et al. 2004]. Cell culture experiments 
proved that PrPC traffics through endocytic compartments and recycles back to the cell 
surface [Shyng, 1993]. Quite notably, internalization of PrPC has been reported to be 
inducible by binding of cupric and zinc ions at the N-terminus and thus may have a 
physiological function in chelating extracellular copper ions [Pauly, 1998; Lee et al. 2001; 
Watt and Hooper 2003]. Interestingly, N-terminal PrPC mutants unable to bind copper or zinc 
ions do not become endocytosed [Perera, 2001]. The biological role of PrPC internalization is 
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unknown. However, this process seems to be crucial for conversion of PrPC to PrPSc 
[Borchelt, 1992]. 
Several internalization processes have been shown to be instrumental in the endocytosis of 
PrPC. Debated are currently clathrin-dependent, caveolin-dependent and clathrin- and 
caveolin-independent internalization pathways [Harris 2003; Prado et al. 2004]. Clathrin-
mediated endocytosis is the uptake of material into cells by which cargo is packaged into 
vesicles using a clathrin coat [McMahon and Boucrot, 2011]. This modular process is 
fundamental to neurotransmission, signal transduction and the regulation of many plasma 
membrane activities. The clathrin-dependent pathway for PrPC internalization was first 
described by the Harris group [Shyng, 1994]. It was demonstrated that the N-terminal region 
of PrPC is essential for its localization in clathrin-coated pits and internalization process 
[Sunyach et al. 2003]. Further studies supported the clathrin-dependent internalization of PrPC 
in the presence of cupric ions [Taylor 2005 and Taylor and Hooper 2007]. This process is 
inhibited by treatment with hypertonic medium which disrupts clathrin lattices. 
Although many studies have proposed that PrPC is endocytosed via a clathrin-dependent 
pathway, other studies have reported that PrPC clusters in raft and/or caveolae-like domains 
[Ying et al. 1992; Vey et al. 1996; Kaneko et al. 1997; Peters et al. 2003; Sunyach 2003]. 
Importantly, raft-disrupting drugs inhibit PrPC internalisation [Marella et al. 2002; Peters et al. 
2003]. More recent results show that PrPC is either internalized in a clathrin-independent 
pathway that is associated with Arf6 [Kang et al. 2009] or in a clathrin-dependent pathway 
[Sarnataro et al. 2009]. 
In summary, there is no consensus how PrPC’s internalization is regulated. 
The Scrapie Prion Protein (PrPSc) 
 
PrP can exist in two different conformational states: a normal (PrPC) and an abnormal or 
alternative isoform of PrP (PrPSc). For both states, the primary structure is the same as encoded 
by the PrP gene. No post-translational modifications differentiate PrPC from PrPSc [Stahl, 
1993]. Differences arise at the level of secondary structure, where α-helical PrPC is converted 
into a mainly β-sheeted PrPSc isoform [Caughey et al., 1991; Gasset et al., 1993; Pan et al., 
1993]. Through these conformational changes, PrPSc gains several new physico-chemical 
properties compared to PrPC, such as partial or full resistance to proteolytic digestion 
[McKinley et al., 1983] or PI-PLC, respectively, as well as a highly-detergent insolubility 
which may be due to a higher β-sheet structure [Caughey et al. 1991; Pan et al. 1993]. 
Incubation of a prion infected brain homogenate with proteinase K under defined conditions 
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results in a complete digestion of PrPC, but not PrPSc. PrPSc loses about 65 aa of its N-terminus 
and maintains its PK-resisitant part. This trait of PrPSc has been served as a surrogate marker 
of prion infection because PrPSc co-purifies with infectivity [Prusiner 1982; Gabizon et al. 
1988]. Attempts to purify PrPSc by fractionation and correlating the mass of the purified 
protein complexes to the infectivity of the samples, indicates that the most infectious prion 
particle is composed of 14-28 PrP molecules [Silveira et al., 2005]. Although limited 
resistance to enzymatic digestion has been proved to be a good tool to detect PrPSc, not all 
PrPSc‘s are resistant to protease digestion [Hsiao et al. 1994]. Furthermore, PrPSc from 
different prion strains or species differ in their susceptibility to protease digestion [Safar et al., 
1998]. Furthermore, PrPSc has the propensity to polymerize into amyloid-like fibrils and 
aggregates [Marsh et al., 1984; Prusiner et al., 1983] and accumulation of PrPSc in the brain 
causes neurodegeneration.  
The existence of prion strains is another puzzling phenomenon in prion biology [Aguzzi et al., 
2007]. Prion strains are defined as infectious prion agents that exhibit distinct disease-
associated phenotypes such as incubation times, histological lesion profiles and neuronal 
targeting that persist upon serial transmission rounds [Pattison and Millson, 1961; Bruce and 
Dickinson 1987; Kimberlin, 1987]. The prion strain phenomenon is explained by the protein-
only hypothesis as follows: PrPSc can obtain different pathological conformations, all of which 
can cause and transmit disease. This is supported by evdence suggesting that different prion 
strains have different stabilities against chaotropic salts and heat [Safar et al., 1998] and 
susceptibility to digestion with PK. In addition, the side of protease digestions can vary with 
different prion strains [Casalone et al., 2004; Zanusso et al., 2004], suggesting a difference in 
the accessibility of the N-terminal part of the PrPSc molecule, supporting the idea that PrPSc 
conformation can encode strain phenotypes. Of note, it has been shown that different strains 
can co-exist within the same individual [Polymenidou et al., 2005; Yull et al., 2006]. 
However, the experimental proof that conformational variants of PrPSc represent the biological 
basis of prion strains is still amiss. Whether the impairment of one or more of PrPCs functions, 
or the gain of a new function by PrPSc, is related to the development of disease in not known 
[Martins et al. 2002; Hetz et al. 2003]. 
Prion Conversion Reaction 
 
Fundamental events in prion propagation and PDs are the presence and the conformational 
change of PrPC into PrPSc. According to the “protein-only” hypothesis, there are two models to 
explain this event (Fig. 1). One of the theories explaining the conversion reaction claim a 
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template-directed process [Cohen et al., 1994] (Fig. 1a). Endogenous PrPC acts as a template 
and is refolded into the pathological isoform upon exogenously introduced PrPSc. A high 
energy barrier may prevent spontaneous conversion processes. Sporadic CJD may come about 
through a very rare spontaneous conversion of PrPC to PrPSc, giving rise to a template-driven 
conversion cascade, possibly with the help of a chaperone (designated “protein X”) [Telling et 
al., 1995] or a non-protein molecule such as glucosaminoglycans or short nucleic acids [Priola 
et al., 2003]. Alternatively, the nucleation-polymeratization hypothesis suggests that PrPSc 
exists in a reversible thermodynamic equilibrium with PrPC (Fig. 1b).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Models for the conversion of normal PrPC into pathological PrPSc  
(a) The “Template-directed refolding model” postulates an interaction between PrPSc and PrPC, which is 
subsequently induced to transform itself into PrPSc. A high energy barrier may prevent spontaneous conversion of 
PrPC into PrPSc. (b) The “nucleation-polymerization model” proposes that PrPC and PrPSc are in a reversible 
thermodynamic equilibrium. Only if several monomeric PrPSc molecules from a highly ordered seed, can further 
monomeric PrPSc entities be recruited and eventually generate larger aggregates with an amyloid structure. 
Within such a crystal-like seed, PrPSc becomes stabilized. Fragmentation of PrPSc aggregates increases the 
number of nuclei, which can then recruit further PrPSc and thus replicate the prion agent [Figure and text from 
Aguzzi and Polymenidou (2004). Mammalian prion biology. One century of evolving concepts. Cell 116:313-
27]. 
 
Only if several monomeric PrPSc molecules are organized into higher-ordered seeds, further 
monomeric PrPSc can be recruited and eventually aggregate to amyloids. Breaking of PrPSc 
aggregates increases the number of seeds, which can recruit further PrPSc and thus results in 
replication of PrPSc [Jarrett & Lansbury jr, 1993]. The seed formation is an extremely slow 
event. According to the “nucleation hypothesis”, the aggregated state and not necessarily the 
misfolded form of PrP, would be an intrinsic property of infectivity. It is believed that PrPC 
enters first a metastable intermediate, partially unfolded state, referred to as PrP* [Weissmann, 
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1991; Cohen et al. 1994] before it interacts with PrPSc to undergo a conversion. 
Experimentally, an assumed PrP* -like state is achieved either by denaturation with GdnHCl 
[Kocisko et al. 1994] or with exposure to sonication [Castilla et al. 2005]. For years, the 
assistance of an ominous “protein X” was haunted the prion field which facilitates to enter the 
PrP* state and enables the conversion of PrPC into PrPSc through PrPC binding. “Protein X” 
has yet to be identified in animals [Tamgüney et al. 2008].  
 
However, testing these hypotheses needs precise knowledge of the structure of both PrPC and 
PrPSc. To date, the 3D NMR resolution structure of  mouse, hamster and human PrPC [Riek et 
al., 1996; James et al., 1997; Hosszu et al., 1999] for example and the study of amyloids has 
provided some suggestions for a possible conversion mechanism [Lu et al., 2007]. However, 
the limited amount of PrPSc and its insolubility compared to PrPC has prevented the generation 
of a high resolution structure of PrPSc and the understanding of the conversion process itself.  
It should be noted, that both models fail to explain some aspects in PDs, suggesting that a 
factor might be missing in the equation. How can it be possible that sporadic PDs occur 
exclusively in elderly patients? If the formation of PrPSc is a rare and random event, sporadic 
CJD should occur both in young, as well as in elderly people. This is not the case. 
Prion Pathogenesis 
 
The mechanisms underlying prion pathogenesis leading to gliosis, spongiosis and neuronal 
cell death are not yet understood. Mice devoid of PrPC do not show any signs of neurode-
generation [Büeler et al., 1992] and abolish prion replication upon intracerebral inoculation 
with prions [Büeler et al., 1993]. Mice expressing a secreted form of PrPC termed “GPI-
anchorless” PrPC replicate PrPSc upon inoculation with prions but do not develop 
histopathological changes [Chesebro et al., 2005]. In addition, spongiosis and behavioral 
changes can be reversed by conditionally removing of PrPC selectively in neurons after disease 
onset [Mallucci et al., 2007]. This illustrates that the expression of membrane bound PrPC is 
required for cellular toxicity. 
Hematopoietic cells are involved in transporting prion infectivity from peripheral entry sites to 
secondary lymphoid organs in which prions accumulate and/or replicate. Functional FDCs 
[Montrasio et al., 2000; Mabbott et al., 2003] and B lymphocytes [Klein et al., 1992] are 
crucial to peripheral prion accumulation. However, it seems that the primary compartment for 
prion neuroinvasion is nonhematopoietic, because it cannot be adoptively transfered by bone 
marrow reconstition [Kaeser et al., 2001; Blättler et al., 1997; Klein et al., 1997]. Prions, taken 
                                                                                                       INTRODUCTION 
___________________________________________________________________________ 
 22 
up by ingestion, are transported by intestinal epithelial cells through the epithelium [Heppner 
et al., 2001]. Neural entry and transit to the CNS of prions may occur by prion uptake by nerve 
endings in the intestine. In addition, the vagal nerve and the sympathetic nervous system are 
involved in the transport of prions to the CNS [Beekes et al., 1996; Glatzel et al., 2001]. 
Prion Diagnosis 
 
As in other diseases, early diagnosis would be beneficial and increases the chances to cure the 
disease. Unlike other infectious diseases caused by viruses or bacteria, PDs are difficult to 
diagnose using conventional methods such as serology or PCR. The diagnosis of PDs is 
further complicated by the uneven distribution of the prion agent in body tissues, with highest 
concentrations found in the CNS and very low concentrations in easily accessible body fluids 
such as blood and urine [Aguzzi & Glatzel, 2005]. Compared to other fields in diagnostics, 
presymptomatic diagnosis in PDs is almost impossible. The earliest possible diagnosis is 
based on clinical signs and symptoms after the disease has considerably progressed. Definite 
diagnosis of PDs is determined post mortem by immunohistochemistry. 
The discovery by Stanley Prusiner and co-workers, in which misfolded PrPSc is the disease 
causing agent of prion diseases, as well as the resistance of PrPSc against proteolytic 
degradation [McKinley et al., 1983], stood for a turning point in prion research and diagnosis. 
These remarkable findings identified PrPSc as a surrogate marker of prion infection. Even 
thirty years after its first description, detection of PK-insensitive prion protein is the gold 
standard for prion diseases and is the basis for all the currently available detection methods 
[Aguzzi and Polymenidou, 2004].  
The most common techniques for measuring PrPC and PrPSc in brain samples are either done 
by Western blotting [Inoue et al., 2005] or by ELISA [Grathwohl et al., 1997] after PK 
digestion. After degradation of PK-sensitive PrP, the remaining resistant form can be 
detected. ELISA enables simmultanous analysis of larger number of samples than Western 
blotting, which represents a major advantage. However, to measure PrPC and PrPSc from a 
huge variety of different sources at the same time, the assay has to be done in a homogeneous 
phase. A popular choice for homogeneous assays is Förster/Fluorescence Resonance Energy 
Transfer (FRET). 
In addition to PK treatment the CDI (conformational dependent immunoassay) assay uses the 
differential binding of antibodies to native or denatured PrPSc. The detection antibody 
recognises a conformation-dependent epitope. It only becomes exposed in the infectious form 
upon denaturation while it is always exposed in the non-infectious form (PrPC) [Safar et al., 
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2005]. Another approach to detect PrPSc is called PMCA (protein misfolding cyclic 
amplification), in which PrPSc can be amplified. Here, PrPSc-containng brain homogenate is 
diluted in normal brain homogenate and after various incubation and sonication cycles, 
amplified PrPSc can be measured [Castilla J et al., 2005]. Although PMCA is a very sensitive 
method, PK-resistant material can be formed in the absence of prions and thereby leading to 
false positive results.  
Luminescent conjugated polymers (LCPs) are able to bind with striking affinity to a variety of 
amyloids. The interaction is measured by characteristic spectral changes specific to distinct 
amyloids upon binding [Sigurdson et al., 2007].  
Prion Drug Treatment  
 
So far no efficient treatments against prion diseases are available [Appleby and Lyketsos 
2011], although many compounds that inhibit prion propagation have been identified in prion-
infected cultured cells [Korth et al., 2001] and in animal models [Pocchiari et al., 1987]. 
These include polysulphated polyanions [Caughey and Raymond 1993], polyamines 
[Supattapone et al. 1999], tetrapyrroles [Caughey et al. 1998], polyene antibiotics [Pocchiari 
et al. 1987], tetracyclic antibiotics [Forloni et al. 2002] and tricyclic compounds [May et al. 
2003]. Polyanions interact and stabilize PrPSc as shown for Congo red [Ingrosso et al., 1995] 
and prolong incubation times in rodent models upon co-inoculation with prions [Caspi et al., 
1998].  
Prion Bioassays 
 
The classical method for measuring prions in vivo consists of inoculating test material into 
susceptible indicator animals [Cuille and Chelle, 1939; Gordon, 1946; Chandler, 1963]. End-
point dilutions of the test material allow precise prion titer determination [Prusiner, 1978]. 
These experiments require a very large number of indicator animals. In addition, these 
bioassays require observation periods which often span the entire life of indicator animals. In 
early studies of scrapie using sheep and goat, incubation periods of one to three years were 
required. The discovery of experimental transmission of scrapie from sheep to mice ushered 
in a new era of prion disease research [Chandler, 1961]. The incubation periods were 
shortened to four to five month. With the generation of transgenic mice that overexpress PrP 
genes, an animal model was found with even shorter incubations times [Carlsen et al., 1994]. 
However, this common technique is expensive and time consuming. The introduction of the 
prion organotypic slice culture assay (POSCA) by Jeppe Falsig et al. 2008 has eliminated 
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some of the concerns listed above [Falsig et al., 2008]. This method allowed a dramatic 
acceleration of prion replication ex vivo.  
The discovery that mouse neuroblastoma cells (N2a) propagate prions derived from sheep 
with scrapie and humans with CJD [Kingsbury et al., 1984; Race et al., 1987], enabled the use 
of cultured cells to study prions. The scrapie cell assay in end-point format (SCEPA) is the 
most common solid-phase in vitro prion assay [Klohn et al., 2003]. It enables the 
quantification of the prion titer in prion-susceptible cells after PK digestion and reduced the 
time of the experiment down to three weeks. This assay has been assessed by exposing cells 
to serial dilutions of prion-infected mouse brain homogenates. The dilution rate which yields 
to a negative outcome in a dot blotting assay for PrPSc has been determined to be the 
infectivity level. The application spectrum of this prion assay can be extended to other cell 
lines and to the use of different prion strains serving as inoculum. [Mahal et al., 2007]. To 
achieve accurate and precise measurement of a large variety of different samples, the 
SCEAPA has to be done in a homogeneous phase, which is much faster to do than 
heterogeneous assays. A popular method for homogeneous assays is Fluorescence Resonance 
Energy Transfer (FRET). 
Förster/Fluorescence Resonance Energy Transfer (FRET) 
 
Principles and Requirements of FRET 
FRET is a distance-dependent and non-radiative energy transfer from a donor fluorophore to a 
light-absorbing acceptor molecule [Selvin et al., 1994] and was first described by Theodor 
Förster in the late 1940s [Förster, 1946; Förster, 1948]. FRET occurs at distances beyond 
orbital overlap and below radiative transfer interactions, between an excited donor 
fluorophore and a ground-state acceptor at distances of 1-20 nm [Geissler et al., 2010]. In 
compliance with the resonance condition, the luminescence energy of the donor must be equal 
to the absorption energy of the acceptor (Fig. 2). Due to FRET, the intensity of the donor 
fluorescence decreases while the intensity of the acceptor fluorescence increases. The FRET 
efficiency of this energy transfer is inverserly proportional to the sixth power of the distance 
between the donor and acceptor molecule (EFRET ~ r-6) which makes FRET extremely 
sensitive to small distances [Stryer & Haugland, 1967]. The distance at which the energy 
transfer is 50% is called the Förster distance or Förster Radius [Förster, 1948]. 
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Figure 2. Principle of donor (green background) and acceptor (red background) interaction in FRET 
a) Energy-level diagram representing excitation of the donor (hυ) followed by inner relaxation (dotted arrow), 
followed by radiative decay (kR), non-radiative decay (kNR), or FRET (kFRET). The energy resonance condition 
[ΔE(donor) = ΔE(acceptor)] is represented by the colored lines connecting donor and acceptor transitions. After 
FRET, the acceptor is in an excited state, followed by raditive or non-radiative decay to its ground-state. b) 
Different energy pathways after donor excitation (hυex) leading to radiative (kR) or non-radiative (kNR) decay of 
the donor or acceptor in case it is excited by FRET (kFRET). D, D* and A, A* indicate the ground or excited state 
of the donor and acceptor, respectively. Figures and text from Geissler et al., 2013. 
 
Currently, lanthanide chelates are predominantly used as donor fluorophores in FRET 
applications. Unlike formerly used organic dyes, they have unique properties. One of their 
characteristics is their extremely long excited-state lifetimes (up to several milliseconds) 
which enable time-resolved (TR) measurement of the acceptor emission. This trick decreases 
the effect of autofluorescence as well as direct acceptor excitation and makes FRET a 
particular sensitive technique. Another one is that their emission spectra are narrow and well 
separated and their Stokes’ shifts are long [Hemmilä and Laitala, 2005]. Several different 
lanthanides (Europium, Terbium, Samarium, Dysprosium) are available with unique spectral 
properties and a large variety of acceptor molecules.  
The Europium chelate [www.PerkinElmer/LANCE] is composed of an emitting Europium 
cation (Eu3+) coordinated by an aromatic ligand, which serves both as a photo-collecting 
antenna and as a protective shield towards interacting solvent molecules. Because of the 
indirect excitation of the Eu3+ through the coordinated ligand, the excitation and emission 
wavelengths of the complex are at different energy levels referring a large Stokes’ shift 
[Hemmilä, 1999]. 
 
Terminology and FRET Assays in Prion Biology 
FRET assays can be categorized into four different classes. They are either competitive or 
non-competitive and are performed either in a homogeneous or in a heterogeneous phase. 
Non-competitive assay formats are defined as the recognizing agent bound to the analyte is 
  
a b 
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the source of the FRET signal. Thus, in non-competitive FRET assays the signal increases 
with increasing analyte concentration. In competitive assays, the signal created by agent is not 
bound to the analyte. Typically, non-competitve assays are considered to have a higher 
sensitivity than competitive ones [Wild et al. 2005]. In heterogeneous assays, the analyte is 
physically bound to a solid-phase. The advantage in this assay format is to remove free label 
or interfering factors by a washing step before measurement. This is not the case in 
homogeneous assays which have no separation step and are often called “mix and measure” 
assays. Homogeneous assays are very popular when the number of samples is large and/or the 
speed of the assay is important. Heterogeneous assays are considered to be more sensitive. 
Recently, a Terbium-based FRET assay was introduced in prion biology by Karapetyan et al., 
2013. Because PrPC is necessary for PrPSc replication, they developed a homogeneous assay 
which enables the detection of PrPC at the surface of living cells. By screening for compounds 
which down regulate cell surface expression for PrPC, they established an unique drug 
screening platform which could also be applied to treat Alzheimer's disease [Karapetyan et 
al., 2013]. 
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AIMS OF THE THESIS 
 
The focus of the current study was to develop FRET-based immunoassays which enable the 
detection of PrPC and PrPSc in high-throughput applications (Fig. 3). The aim is to use this 
novel platform to perform RNAi, substance and drug screenings. 
 
More specifically the aims were: 
 
Part I Development of a sandwich ELISA which discriminates between PrPC and 
PrPSc  
To assess whether the FRET technology can be applied to detect PrPC and PrPSc in cell 
lysates, the first goal was to develop a sandwich ELISA which discriminates between both 
PrP isoforms. More specific aims were: 
(i) To generate chronically prion-infected cells and determination of PK-resistant material 
by SCA and Western blotting.  
(ii) Because PrPSc resembles repeated aggregates of misfolded PrPC, detection of PrPSc 
with the same antibody twice should be tried [Pan et al., 2005] otherwise PK digestion 
of cell lysates and denaturation of PrPSc should be considered.  
(iii) Among the anti-PrP POM antibody library the best ELISA antibody combination 
should be identified by the detection limit of PrPSc and by the signal-to-noise ratio. By 
calculating the Z’ factor for the PrPSc sandwich ELISA, the feasibility for further 
development into a homogeneous FRET-based application with high-throughput 
potential should be determined.  
To further validate the PrP ELISA, results should be compared and correlated with two other 
prion assays, the SCA and the protein misfolding assay. Furthermore, the PrP ELISA should 
be applied to answer the question whether LCP treatment influence prion replication in 
cerebellar slice culture tissues. 
 
Part II Development of FRET-based immunoassays which detect recPrP, PrPC 
and PrPSc 
The goal of this project was to establish TR-FRET-based high-throughput methods for 
detection and quantification of various PrP species.  
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(i) The first aim was to detect recPrP in a homogeneous phase in a 384-well plate format 
by FRET. To achieve this aim, the best FRET antibody pair has to be determined 
according to the limit of detection for recPrP and to the signal-to-noise ratio. 
(ii) The second aim was to determine the amount of PrPC and PrPSc in prion-infetced cell 
lysates and brain homogenates by FRET. Therefore, best lysis, digestion and 
denaturation conditions for PrPC and PrPSc have to be evaluated. Various POM 
antibody combinations should be tested and validated according to the limit of 
detection for PrPC and PrPSc and to the signal-to-noise ratio. By calculating the Z’ 
factor for each PrP FRET assay, the feasibility for automatisation by robotics at a 
high-throughput level should be determined. 
(iii) The third aim was to detect PrPC on the surface of living cells in the 384-well plate 
format. In cell titration experiments, best FRET antibody combination should be 
determined according to the limit of detection for PrPC and to the signal-to-noise ratio. 
The feasibility to monitor changes of PrPC cell surface expression by FRET should be 
tested. The principle that the FRET signal intensity depends on distance should be 
applied to study the internalisation of PrPC in living cells. If this is possible, siRNA 
treatment should be done to study genes involved in the internalisation of PrPC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Aims of the thesis 
To discriminate between normal PrPC and infectious PrPSc, samples are lysed and digested with proteinase K 
(PK). After PK inactivation, PrPC and PrPSc are detected by a solid-phase sandwich ELISA (Part I) or by a 
homogeneous FRET-based immunoassay (Part II). 
 
 
 
[Adriano Aguzzi, 2010] 
Part II homogeneous FRET-based immuno assay 
Part I        solid-phase sandwich ELISA 
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PART I RESULTS  
PrPC and PrPSc Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Principle of the Sandwich ELISA 
An ELISA is an analytical test which uses antibodies to detect a substance [Crowther, 2001]. 
The substance, usually an antigen in liquid solution, is immobilized on a solid support either 
non-specifically via adsorption or specifically by catching via a particular antibody to the 
surface. A sandwich ELISA is a solid-phase enzyme immunoassay which needs at least two 
antibodies, a catching and a detection antibody. Usually, a polystyrene microtiter plate is 
coated with a specific catching antibody which binds the antigen on the plate. By adding the 
detection antibody a complex is formed with the antigen. The detection antibody can be 
directly linked to an enzyme or indirectly via a second antibody conjugated with an enzyme. 
The addition of the enzyme’s substrate produces a signal which is proportional to the antigen-
enzyme complex. Between each step, the plate is typically washed with a mild detergent 
buffer to remove unbound and unspecific sample [Crowther, 2001] (Fig. 4a). 
To develop a sandwich ELISA which detects PrPC and PrPSc from various biological samples, 
I used our in-house PrP targeting POM antibody library [Polymenidou et al., 2008; Sonati et 
al., 2013]. More than 15 different in-house monoclonal antibodies are available for PrP 
detection (Fig. 4b). 
 
 
 
 
 
 
Figure 4. Principle of the solid-phase sandwich ELISA and anti-PrP POM antibody library 
(a) Principle of a sandwich ELISA. A clear 96-well microtiter plate is coated with the capture antibody and 
sample is added (1). Any antigen within the sample binds to the capture antibody (2). Detection antibody with a 
biotin tag is added and binds to immobilized antigen (3). Avidin-HRP conjugate is added and binds to the 
biotinylated detection antibody. HRP enzyme substrate is added and converts to a detectable signal (4) and (5). 
(b) Schematic illustration of PrP and its POM antibody epitopes. The POM1 and POM19 antibody recognises 
PK-resistant epitopes at the C-terminus of PrP. The POM2 antibody has four binding epitopes [Figure was taken 
from Sonati et al., (2013). The toxicity of antiprion antibodies is mediated by the flexible tail of the prion 
protein. Nature 501:102-106]. 
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In order to develop an ELISA that discriminates between PrPC and PrPSc from prion-infected 
cell lysates, various parameters were tested. First, a prion infectivity protocol was established 
for several different murine cell lines. Prion infectivity was measured from various prion 
strains by the scrapie cell assay (SCA) and a time course analysis of prion-infection was done. 
To detect PrPSc by ELISA, cell lysis conditions, proteolytic digestion and its inactivation, as 
well as a denaturation step was tested. 
 
Prion Infectivity Protocol for Murine Cell Lines 
 
To infect cells with prions, I used a protocol which is used in the SCEPA [Klohn et al., 2003]. 
Prion susceptible cells were co-cultured with prions originating from brain homogenates of 
terminally sick mice. Several cell splits are necessary to get rid of the initial inoculum. Two 
different murine cell lines were tested, namely neuroblastoma-derived N2aPK1 and 
hippocampal CAD cells. Hpl PrP-deficient (Hpl KO) cells were used as negative controls. All 
cell lines were infected with two different prion strains: RML and Me7. To determine PrPSc in 
lysates, cells were digested with PK at different concentrations. PK inactivation was done by 
heating. PrPC and PrPSc detection was assessed by Western blotting using the POM1 antibody 
(Fig. 5a). In the presence of 5 to 20 µg/ml PK no PrPC was detectable in non-infected N2a 
cells. In contrast, RML-infected N2a cells (N2aRML) digested with even 10 µg/ml PK 
showed a weak signal for PrPSc. Prion infectivity was determined by SCEPA (Fig. 5b). Here, 
20’000 non-infected cells (N2a, CAD, Hpl KO) were either inoculated with RML or Me7 
prion strain with prion titers ranging from 10-3 to 10-8. After every third day, cells were 
harvest from the flaks and diluted 1 to 10. This process was repeated two times. No initial 
inoculum was detected in Hpl PrP KO cells after three 1:10 cell splits. Both cell lines showed 
different properties in prion replication. Me7-infected N2a cells showed a lower replication 
rate of prions compared to RML-infected N2a cells. In contrast, both prion strains replicated 
at a higher level in CAD cells. These results are in line with earlier published reports [Mahal 
et al., 2007]. According to literature, prion replication in cells decreases after several cell 
splits. For that, prion titer of RML-infected N2a cells was monitored from three to 20 1:10 
cell splits. Prion titer decreased after 20 splits about 1 log unit (Fig. 5c). For the further 
experiments, I decided to use N2a cells infected with the RML prion strain at a concentration 
of 10-4. N2aRML cells were used only to the 10th cell passage.  
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Figure 5. Western blot analysis, scrapie cell assay (SCA), and prion titer time course analysis 
(a) The Western blot shows the PrPC and PK-resistant PrPSc levels of N2a and N2aRML-infected cells. PrPC 
levels of non-infected N2a cells disappeared in the presence of 5 µg/ml PK. PrPSc is still detectable at a PK 
concentration of 10 µg/ml. (b) Prion titers of RML- or Me7-infected N2a or CAD cells from three different 
biological samples are shown. (c) Summarized are the prion titers of N2a cells infected with 10-4 RML during 18 
cell splits. Shown are biological triplicates. 
 
Cell Lysis Conditions 
 
In a first set of experiments, I tested various cell lysis conditions, such as the concentration of 
different detergents as well as temperature. In a clear 96-well plate, 20’000 non-infected and 
RML-infected N2a cells were plated and digested in TBS buffer in the presence of 0.3, 1.5 
and 3% of either Tween20 or TritonX100 at 37°C or 4°C for 30 min. Protein concentration 
was assessed by Bradford assay (Fig. 6). The digestion with Tween20 and TritonX100 was 
more efficient in N2a cells at 37°C and at the highest detergent concentration used than at 4°C 
with the same concentrations (Fig. 6a/c). In N2aRML-infected cells, lysis was more efficient 
at 4°C compared to 37°C (Fig. 6b/d). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Cell Lysis conditions  
In (a) are shown cell lysis conditions of Tween20 in N2a cells at two different temperatures. In (b) for N2aRML 
cells. The same experiments were done with TritonX100 in N2a (c) and N2aRML cells (d). Shown are biological 
duplicates. 
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Proteinase K (PK) Digestion and its Inactivation 
 
The gold standard assay for assessing the detection of PrPSc relies on the resistance to 
digestion with proteinase K (PK) [Bolton et al., 1982]. The native PrPC protein is sensitive to 
hydrolysis by proteases (PK, trypsin, SV-8), PrPSc only partially. However, denaturation by 
boiling in sodium dedecylsulfate (SDS) or β-mercaptho-ethanol rendered PrPSc susceptible to 
proteolytic digestion [McKinley et al., 1983]. The relative resistance of PrPSc to PK depends 
on the activity of PK [McKinley et al., 1983], on lysis conditions [Madec et al. 1997; Oesch et 
al 1994], on the concentration of non-PrP contaminants and prion strains.  
The first goal was to combine cell lysis and PK digestion in a single step. For that, PK 
enzyme was titrated in the presence of N2aRML cell lysate under different lysis conditions in 
a clear 96-well plate. Normal N2a cell lysate was used as a negative control. Various ionic 
and non-ionic detergents at various concentrations and different combinations were tested 
(Fig. 7). The lysis and digestion was performed at 37°C for 30 min. The detergent influences 
the PK resistance of PrPSc, either by enhancing or diminishing signal intensity. Best lysis and 
digestion conditions were found with TBST (Tris-HCl pH 7.5 + 1.5% Triton X100) for 30 
min at 37°C on a shaking platform (600 rpm) (Fig. 7c). Cell lysates were subjected to 
digestion with various concentrations of PK. PrPC and PrPSc content was detected by 
sandwich ELISA with POM1 as catching and biotinylated-POM19 as detection antibody. 
Digestion of 50 µg total protein concentration with 10 µg/ml PK in a reaction volume of 50 µl 
(corresponding to 1 mg/ml total protein concentration) was found to ensure complete and 
consistent removal of PrPC in N2aRML cell lysates.  
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Figure 7. Cell lysis conditions and PK titration in a single step (opposite page) 
In all experiments, N2a and N2aRML cells were digested with the same concentrations of PK ranging from 0 to 
50 µg/ml. At the same time, cell lysis occurred in the presence of various detergents at different concentrations, 
such as (a) Tween20 1.5%, (b) Tween20 3%, (c) TritonX 1.5%, (d) TritonX 3%, (e) Tween20/TritonX 1.5%, (f) 
Tween20/TritonX 3%, (g) SDS 1.5%, (h) SDS 3%. Digestion with saponin (not shown) gave similar results as 
digestion with SDS. All experiments were performed at 37°C during shaking. Shown are triplicates. 
 
One way to inactivate PK is by heating the samples at 95°C for ten min, which is suitable for 
small sample sizes, for example in Western blotting experiments [Bolton et al., 1982]. This 
procedure is inapplicable in ELISA experiments when working in the 96-well plate format. 
Here, PK’s activity was halted by the cysteine proteinases inhibitor phenylmethylsulfonyl 
fluoride (PMSF). To determine PK inactivation, PrP-deficient Hpl cell lysate was digested 
with 10 µg/ml PK for 30 min at 37°C. Different concentrations of PMSF were either added or 
not for 10 min and thereafter spiked with recPrP for 10 min. Results in Fig. 8 showed that 2 
mM or higher concentrations of PMSF were sufficient to block the activity of PK. For all 
further experiments, 10 µg/ml PK was inactivated by 2 mM PMSF for 10 min at room 
temperature during stirring. 
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Figure 8. PK inactivation by addition of PMSF 
Hpl cell lysate was digested with a constant concentration of 10 µg/ml PK for 30 min at 37°C during shaking. 
The PK inhibitor PMSF was added at different concentrations for 10 min. To show PK inactivation, samples 
were spiked with recPrP and incubated for further 10 min. POM1 was used as coating antibody, biotinylated 
POM19 antibody as primary one. Shown are hexaplicates. 
 
Denaturation of PrPSc with Guanidinium Thiocyanate (GdnSCN) 
 
Attempts to detect PrPSc by ELISA after proteolysis with only PK digestion were not 
sufficient. Detection of PrPSc can be enhanced by including a denaturation step which loosens 
the aggregated state of the PrPSc particles and therefore unmasks some PrP epitopes. The 
effect of the chaotropic salt GdnSCN (guanidinium (Gdn), thiocyanate (SCN)) was explored 
on a recPrP standard curve. GdnSCN was diluted 1:1 in NaHCO3 to an end concentration 
ranging from 0.2 to 3 M and then incubated with recPrP for 10 min at room temperature. 
Samples were transferred into a POM1-coated plate and detection was done via biotinylated-
POM19 antibody. An increase in RFU was observed for up to 0.5 M GdnSCN. The signal 
decreased with increasing GdnSCN concentrations (Fig. 9), presumably by interfering with 
both antibodies. For all following experiments, samples were denatured with 3 M GdnSCN 
and diluted with 0.1 M NaHCO3 pH 8.9 to an end concentration of 0.5 M GdnSCN. 
 
 
 
 
 
 
 
 
0
10000
20000
30000
40000
RL
U/
ng
 re
c 
Pr
P
PK [10 µg/ml]         - +          - +         +         +         +
PMSF [mM]         - - - - 2         5        10
recPrP [100 ng/ml]        - - +         +         +         +         +
RL
U/
ng
 re
c 
Pr
P
 
PART I                                                                                                                       RESULTS                                                                         
___________________________________________________________________________ 
 35 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Titration of the denaturation agent GdnSCN  
Increasing concentrations of GdnSCN/NaHCO3 were added to recPrP at the indicated concentrations and 
incubated for 10 min at room temperature. Samples were transferred onto a POM1-coated plate and detected 
with biotinylated POM19 antibody. Shown are monoplicates. 
 
Antibody Titration 
 
Forced through the conformational change of PrPC to PrPSc, the C-terminal part of PrPSc 
becomes protease resistant. Therefore, only protease-insensitive POM-epitopes, mainly 
located at the C-terminus of PrP, enable the detection of PrPSc by sandwich ELISA. The first 
choice was the POM1/POM19 antibody pair, many times used in PrPSc Western blot 
experiments. Both POM1 and POM19 were tested either as coating or as biotinylated primary 
antibody. Titration experiments were performed at a constant amount either with recPrP or 
N2a cell lysate. Better results were found when using POM1 as coating antibody.  
At a POM1 concentration of 400 ng/ml, the saturation point was reached for recPrP (Fig. 10a) 
as well as PrPC from crude cell lysate (Fig. 10b). Titration experiments for biotinylated 
POM19 antibody with recPrP and N2a cell lysate are shown in Fig. 10c and d. The 
concentration of POM1 as coating antibody was kept constant at 400 ng/ml. For all further 
experiments, biotinylated POM 19 antibody was used at a concentration of 1 µg/ml. 
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Figure 10. Titration of coating and primary biotinylated POM antibodies 
To determine the optimal concentration of the coating antibody, a clear 96-well plate was coated overnight with 
different concentrations of POM1 antibody in coating buffer. Test samples were either recPrP (5 ng/ml) (a) or 
N2a cell lysate (300 µg/ml) (b). Biotinylated POM19 was kept constant at a concentration of 400 ng/ml. In (c) 
and (d) the detection of recPrP and PrPC in cell lysates, respectively, with the primary POM19 antibody are 
shown. Shown are the mean of hexaplicates ± standard deviations. 
 
Limit of Detection (LOD) for recPrP and PrPSc Detection 
 
To estimate the detection limit (LOD) of recPrP, a 96-well plate was prepared with recPrP 
serially 1:1 diluted in Hpl PrP KO cell lysate. The LOD for recPrP was determined at a 
concentration of 1.5 ng/ml (Fig. 11a). When denatured with GdnSCN, LODs were obtained 
for concentrations lower than 0.5 ng/ml. To determine the LOD of PrPSc, crude N2aRML cell 
lysate at an initial concentration of 100 µg/ml was serially 1:1 diluted in normal N2a cell 
lysate at a constant concentration of 100 µg/ml in the presence or absence of PK. A 
statistically significant result for PrPSc detection from RML-infected N2a cells was found for 
6 µg/ml total protein concentration (Fig. 11b).  
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Figure 11. LOD for recPrP and PrPSc  
(a) End point titration curve of recPrP. Dashed line represents detection limit of recPrP. Error bars represent 
standard deviations from 6 replicate wells. (b) Titration curve of PrPSc (N2aRML) spiked with PrPC (N2a) in the 
presence or absence of PK. Error bars represent standard deviations from 6 replicate wells.  
 
Validation of the PrP ELISA 
 
To judge whether the PrPSc ELISA can be developed to a FRET-based high-throughput 
screening assay, the Z’ factor was measured. The Z’-factor is defined in terms of four 
parameters: the means (µ) and standard deviations (σ) of both the positive (p) and negative 
(n) controls (µp, σp and µn, σn) (Fig. 12). RML- and non-infected N2a cells were digested 
with 10 µg/ml PK and inactivated with 2mM PMSF. Protein cell lysate was denatured with 
3M GdnSCN and neutralized by NaHCO3 to an endconcentration of 0.5 M. Cell lysates were 
transferred into a POM1-coated 96-well plate. Biotinylated POM19 was used as primary 
antibody. The %CV values for N2a (n=44) was 18.88% and for N2aRML (n=44) 6.98%. A 
Z’-factor of 0.58 was obtained, which corresponds to an excellent assay. The Z’-factor is large 
enough to warrant further attention and to establish a homogeneous FRET based assay for 
detection of recPrP, PrPC and PrPSc. 
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Figure 12. Determination of the Z’-factor of the PrP ELISA (opposite page) 
Calculation of the Z factor, separation band and dynamic range. Error bars represent standard deviations from 44 
replicate wells. 
 
 
Detection of PrPSc with the same Coating and Primary POM Antibody by ELISA 
 
PrPSc occurs as aggregates of PrPC. We reasoned whether the same POM antibody could be 
used as coating as well as primary antibody to detect higher aggregated PrPSc. The reason for 
that is that the same epitope may occur several times in the aggregated isoform. The first 
choice was the POM1 and POM19 antibodies. Both antibodies were tested in normal and 
RML infected cell lysates under various lysis conditions in the presence of PK. Control 
experiments were done in the absence of PK. Under these conditions, neither the POM1 and 
POM19 antibody nor another member of the POM antibody family enabled the detection of 
PrPSc (Fig. 13). 
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Figure 13. Dectetion of PrPSc with the same POM antibody twice (opposite page) 
PrPC and PrPSc was detected with the POM1 antibody as capture and primary antibody without (a) and after PK 
(b) with CHAPS, NP40 (c and d), Tween20 (e and f) and TritonX100 (g and h). PrPC and PrPSc was detected 
with the POM19 antibody as capture and primary antibody without (i) and after PK (j) with CHAPS, NP40 (k 
and l), Tween20 (m and n) and TritonX100 (o and p). 
 
Detection of N-GPI-PrPC  
 
The use of the same antibody twice as coating and detecting antibody is possible to detect 
PrPC. Here, the ELISA was used to detect and quantify N-GPI-PrPC expressend in transgenic 
mice. The N-GPI-PrPC is a deletion mutant of the prion protein which mainly comprises the 
octapeptide repeat at the N-terminus and the GPI anchor (PrP∆144-225). The N-GPI-PrPC 
level was monitored from brain homogenates of animals at different ages (day 68 to day 76) 
and detected either with the POM2/POM2 (Fig. 14a), the POM2/POM11 (Fig. 14b) or the 
POM11/POM2 (Fig. 14c) ELISA antibody combinations. The POM2 epitope occurs four 
times, whereas the POM11 epitope is two times present within the octapeptide repeat region 
of PrP. In control experiments, recPrP titration curves were used. In all three experiments, an 
age-dependent increase in N-GPI-PrPC levels could be monitored. Spiking experiments of 
recPrP in Hpl PrP KO cell lysates confirmed the data found for N-GPI-PrPC detection (Fig. 
14d).  
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Figure 14. Dectetion of NGPI-PrPC and recPrP with N-terminal POM antibodies 
N-GPI-PrPC was detected with POM2/POM2 (a), POM2/POM11 (b) and POM11/POM2 (c) in mice at the age 
of 68 day (d68) to 76 days (d76). KO = knock out PrP brain homogenate. In (d), the detection of recPrP is 
shown, spiked with Hpl KO cell lysate using the same antibody combinations. 
 
PTAA Drug Treatment of Prion-Infected Tissue Cultures 
 
The Prion Organotypic Slice Culture Assay (POSCA) 
 
In collaboration with Ilan Margalith the effect of PTAA on prion replication and prion 
infectivity was studied ex vivo [Margalith et al., 2012]. We used the POSCA, a cerebellar 
slice culture system introduced by Jeppe Falsig [Falsig and Aguzzi, 2008; Falsig et al., 2008]. 
The POSCA is a flexible tool which allows the manipulation of the tissue such as compound 
treatment via culture media as well as specific cell type depletion or addition.  
The experimental setup is summarized in Fig. 15. Cerebellar organotypic slices were 
produced from 11 day old PrPC-overexpressing tga20 mice and inoculated with RML prions. 
At day 21, the PTAA drug treatment started. The drug was administered in the slice culture 
media three times per week. PrPSc was measured by ELISA after PK digestion and 
denaturation. 
 
 
 
 
 
 
 
 
Figure 15. Experimental set up. PTAA treatment of RML-infected cerebellar tissue cultures. 
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Total PrP expression (PrPC + PrPSc) was obtained without digestion. PrPC expression was 
calculated by the subtraction of total PrP from PK-digested one. PTAA-treated, chronically 
infected cerebellar slice cultures have less PK-resistant material than untreated cultures (Fig 
16a). The decrease in PrPSc load depends on PTAA concentration and strongly correlated with 
the SCEPA and MPA data (Fig 16c and d). At the concentration of 60 µg/ml PTAA, no PK-
resistant PrP could be detected by ELISA. Calculated PrPC expression levels were relatively 
constant and showed no statistically significant difference except for slices treated with 60 
µg/ml PTAA, which showed a significant reduction in PrPC levels (Fig 16b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PART I                                                                                                                       RESULTS                                                                         
___________________________________________________________________________ 
 42 
 
 
 
 
 
 
 
Figure 16: PTAA treatment of COCS decrease PK-resistant material measured by ELISA. 
(a) PrPSc levels of COCS brain homogenates are shown. Each dot represents the average value of technical 
duplicates for one COCSBH. Error bars represent the mean ± SEM of biological triplicates. All data were 
normalized to protein concentration of the corresponding sample. P-values represent difference to control and are 
shown in Table 3. (b) The calculated PrPC levels of COCS brain homogenates are shown. P-values represent 
difference to control and are shown in Table 4. (c) Correlation diagram to show the relationship between the 
SCEPA and ELISA data. (d) Correlation diagram to show the relationship between the MPA and ELISA data. 
Figures are taken from Margalith et al., 2012. 
 
In the next set of experiments, we wanted to monitor the effects of PTAA treatment in a time-
course analysis. Prion-infected slices were prepared in biological duplicates and the tissue 
was harvested at 7, 19, 21, 28, 35, 42, 45, 49 and 56 DIV. In parallel, prion-infected cultures 
were treated at a constant concentration of 10 µg/ml PTAA and administrated from day 7, 19, 
21, 28 and 35. All cultures were harvested at 42 DPI and PrPSc and PrPC levels were 
determined by ELISA. PK-resistant PrP in untreated tissue could be detected at 21 DIV and 
increased during the course of the experiment. Treatment with 10 µg/ml PTAA from day 28 
kept the level of PK-resistant PrP at the level of the corresponding time point in untreated 
tissue, whereas treatment started from day 35 resulted in a decrease of detectable PK-resistant 
PrP. It cannot be excluded, however, that PTAA treatment induces a modification of PrP 
aggregates that interferes with the ELISA assay. PrPC levels of the cerebellar tissues are 
shown in Fig. 17c. PTAA treatment started at either time-point decreased PrPC levels about 
two fold. This confirms that PTAA treatment might affect prion accumulation by reducing the 
amount of PrPC or of a transition intermediate to PrPSc. 
 
 
 
 
 
 
 
 
c 
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Figure 17. PTAA inhibits prion accumulation in RML6-infected slice cultures from different time points  
(a) MPA of homogenates from RML6 infected slices harvested at days 7, 19, 21, 28, 35 and 42 DIV. PTAA was 
administered at a concentration of 10 µg ml-1 at the time of medium change freshly into the medium from  
days 7, 19, 21, 28 or 35 DIV. Slice cultures were harvested at 42 DIV and analyzed for PrP aggregates. Each dot 
represents the average value of technical triplicates for one slice culture homogenate. Error bars represent the 
mean ± SEM of biological duplicates. All data were corrected for non-infectious brain homogenates obtained 
from CD1 mice as negative control (mock) and represented as the ratio between relative light units (RLU) and 
protein concentration for each sample. P-values are shown in Table 5. (b) Sandwich ELISA of the same 
homogenates as in (A) analysed for PrPSc. The data are represented as biological triplicates. The signal for the 
negative control (mock) is shown as single replica. (c) Sandwich ELISA of the same homogenates as in (A) 
analysed for PrPC. The ELISA was developed by chemiluminescence. The detection limit of 600 pg ml-1 (dashed 
line) was determined as the mean background levels plus three times SD. Figures taken from Margalith et al., 
2012. 
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Table 2 (Data taken from Margalith et al., 2012) 
Statistical analysis of data shown in Figure 16a using a one-way ANOVA with Tukey’s 
multiple comparison test. 
Figure 16a p-value 95% c.i. of difference 
untreated (21 DIV) p < 0.001 -41.79(-66.96 to -16.62) 
PPS 0.3 µg/ml p < 0.001 37.56(12.39 to 62.73) 
PTAA 60 µg/ml p < 0.001 42.94(17.77 to 68.11) 
PTAA 6 µg/ml p < 0.001 40.57(15.40 to 65.74) 
PTAA 1 µg/ml p < 0.001 35.09(9.917 to 60.26) 
PTAA 0.1 µg/ml p < 0.001 26.51(1.36 to 51.70) 
PTAA 0.01 µg/ml p = 0.450 12.11(-13.06 to 37.28) 
 
Table 3 
Statistical analysis of data shown in Figure 16b using a one-way ANOVA with Tukey’s 
multiple comparison test. 
Figure 16b p-value 95% c.i. of difference 
PTAA 60 µg/ml p < 0.05 47.70(0.65 to 94.75) 
 
Table 4 
Statistical analysis shown in Figure 17 using a one-way ANOVA with Tukey’s multiple 
comparison test. 
Fig. 17a p-values 95% c.i. of difference 
7 DIV ns -9(-108.8 to 90.80) 
19 DIV ns -13.86(-113.7 to 85.94) 
21 DIV ns -23.77(-123.6 to 76.03) 
28 DIV ns -60.36(-160.2 to 39.44) 
35 DIV p < 0.001 -205.5(-305.3 to -105.7) 
42 DIV p < 0.001 -252.8(-352.6 to 153.0) 
From 7 DIV ns -2.11(-101.9 to 97.68) 
From 19 DIV ns -1.26(-101.1 to 98.54) 
From 21 DIV ns 0(-99.80 to 99.80) 
From 28 DIV ns -0.49(-100.3 to 99.30) 
From 35 DIV ns -0.04(-99.84 to 99.75) 
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Fig. 17b p-values 95% c.i. of difference 
7 DIV n/s 0(-38 to 38) 
19 DIV n/s -0.09(-38 to 38) 
21 DIV n/s -0.95(-39 to 37) 
28 DIV n/s -6.2(-44 to 32) 
35 DIV n/s -16(-54 to 21) 
42 DIV p < 0.001 -54(-92 to -17) 
45 DIV p < 0.001 -113(-151 to -76) 
49 DIV p < 0.001 -114(-152 to -76) 
56 DIV p < 0.001 -114(-152 to -77) 
From 7 DIV n/s -0.43(-38 to 37) 
From 19 DIV n/s 0(-38 to 38) 
From 21 DIV n/s 0(-38 to 38) 
From 28 DIV n/s -4.6(-42 to 33) 
From 35 DIV n/s -21(-59 to 17) 
42 DIV vs. from 7 DIV p < 0.001 54(16 to 92) 
42 DIV vs. from 19 DIV p < 0.001 54(17 to 92) 
42 DIV vs. from 21 DIV p < 0.001 54(17 to 92) 
42 DIV vs. from 28 DIV p < 0.01 50(12 to 87) 
42 DIV vs. from 35 DIV n/s 33(-4.5 to 71) 
   
Fig. 17c p-values 95% c.i. of difference 
7 DIV ns 44(-174 to 261) 
19 DIV ns 71(-146 to 289) 
21 DIV ns 67(-151 to 284) 
28 DIV ns 52(-165 to 270) 
35 DIV ns 162(-55 to 380) 
42 DIV ns 53(-165 to 270) 
45 DIV ns 107(-110 to 325) 
49 DIV ns 14(-203 to 232) 
56 DIV ns 88(-130 to 305) 
From 7 DIV ns 211(-6.6 to 428) 
From 19 DIV ns 196(-22 to 413) 
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From 21 DIV p < 0.05 223(5.7 to 441) 
From 28 DIV ns 189(-28 to 407) 
From 35 DIV p < 0.05 236(18 to 453) 
42 DIV vs. from 7 DIV ns 158(59 to 376) 
42 DIV vs. from 19 DIV ns 143(-74 to 361) 
42 DIV vs. from 21 DIV ns 170(-47 to 388) 
42 DIV vs. from 28 DIV ns 136(-81 to 354) 
42 DIV vs. from 35 DIV ns 183(-34 to 400) 
 
Statistical analysis using a one-way ANOVA with Tukey’s multiple comparison test was done 
by Ilan Margalith. Unless stated otherwise, time points are compared to the non-infected 
COCS. For 42 DIV vs. From 7 DIV, for instance, the value obtained for COCS harvested at 
42 DIV is compared to the value obtained for COCS harvested at 42 DIV with treatment from 
7 DIV. 
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DISCUSSION 
PrPC/PrPSc Sandwich ELISA 
 
In order to establish a sandwich ELISA which detects PrPSc from cell lysates I first developed 
a protocol to efficiently infect cells with prions. For that purpose, infection of two different 
cell lines with two different prion strains was compared. First, murine neuroblastoma N2a 
cells were infected with RML and Me7 prions, respectively. Infectivity titers were assessed 
by SCA. The data showed that N2a cells replicated RML prions more efficiently compared to 
the Me7 prion strain and had therefore a higher prion titer of 7.5 compared to 5 for Me7. CAD 
cells were able to replicate both prion strains with a prion titer between 6 and 7. This is in 
accordance with the literature [Klohn, 2003; Mahal et al. 2007]. The presence of PrPSc in 
RML-infected cells was determined by PK digestion and assessed by western blotting. A 
concentration of 5 µg/ml PK is sufficient to eliminate PrPC in non-infected N2a cells. Prion-
infected cells in culture showed a decreased prion titer over several cell splits. For that reason, 
prion infectivity in RML-infected N2a cells was monitored over 18 cell splits. As shown in 
Fig. 2c, a ten-fold reduction of prion titer could be determined during the cell splits. 
Therefore, chronically RML-infected N2a cells were only used from passage 3 to 9 in all 
experiments. 
Next, I combined cell lysis and PK digestion in a one step procedure. Lysates from RML-
infected cells were exposed to several detergents at different concentrations and were tested in 
the presence of various PK concentrations for 30 min at 37°C. Best cell lysis and digest 
conditions were found when 1.5% TritonX100 was used in the presence of 10 µg/ml PK. A 
concentration of 5 mM PMSF was identified as best condition to halt the action of PK.  
I was not able to detect PrPSc from RML-infected N2a cell lysates after cell lysis and PK 
digestion, presumably because the binding epitopes were buried inside the aggregates. 
Therefore, cell lysates had to be denatured after lysis and proteolytic digestion. This was done 
by GdnSCN which was diluted with NaHCO3 to obtain different GdnSCN concentrations. An 
end concentration of 0.3 to 0.5 M GdnSCN did not interfere with the ELISA antibodies. 
Therefore, cell lysates were denatured with 3 M GdnSCN and diluted six times with NaHCO3.  
Several POM antibody combinations were tested. Best results were found when using POM1 
as capture antibody at a concentration of 0.4 µg/ml per well and biotinylated-POM19 
antibody at a concentration of 1 µg/ml for detection.  
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The detection limit for recPrP was determined at a concentration of 40 ng/ml. PrPSc was 
detected from 6 µg/ml total RML-infected cell lysate. In organotypic slice cultures, PrPSc was 
detected 19 weeks after inoculation with prions which corresponds to a limit of detection of 
about 400 ng/ml recPrP. However, it will require highly purified PrPSc to precisely determine 
the sensitivity. 
Aggregated PrPSc contains hidden epitopes while other epitopes might be present more than 
once. The number of epitopes for binding depends on the composition of aggregated PrPSc. 
Theoretically, it might be possible to use the same POM antibody twice, as capture and 
detecting antibody, to detect PrPSc [Pan et al., 2005]. However, PrPC dimers have also been 
reported in cells [Priola et al., 1995]. None of the tested POM antibodies showed increased 
binding avidity to PrPSc. Therefore, if some aggregated PrPSc is present in the cell lysate it is 
not possible to dectect it under the tested conditions with the same antibody used as capturing 
and detection antibody. 
 
PTAA Drug Treatment of Prion-Infected Slices 
 
We have previously shown that LCPs interact with amyloids and PrPSc [Sigurdson et al., 
2007]. The fluorescence spectra formed by PrPSc-LCPs complexes allows differentiation of 
different prion strains. Theses findings prompted us to test whether the stability of PrPSc 
aggregates and their infectiousness may be affected by interactions with PTAA, a member of 
the LCP family. 
In this study [Margalith et al., 2012], the established ELISA was used to detect PK-resistant 
material in PTAA-treated prion-infected cerebellar slice culture tissues. In PTAA-treated 
cultures, less PK-resistant material could be detected by ELISA than in untreated cultures in a 
PTAA concentration dependent manner. The operating characteristics of the ELISA have 
been further evaluated against two other assays: SCEPA and MPA (misfolding protein assay 
[Novartis]). The ELISA results are perfectly in line with the parallel observations of 
decreased prion infectivity in the SCEPA and decreased prion aggregates in the MPA and 
further point towards a decreased prion load in PTAA-treated tissue. Of note, a good 
correlation between the entities measured by MPA, SCEPA and ELISA indicates that the 
same entity is being affected by PTAA which results in a decrease of measurable PrPSc 
aggregates and infectivity. Treatment with 60 µg/ml PTAA resulted in a prion load of cultures 
that lies below that of tissue harvested at 21 DIV.  
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In addition, we performed PTAA treatment in a time-resolved manner and investigated PrPC 
and PrPSc levels by ELISA. This analysis revealed that PTAA treatment is most effective if 
initiated before 21 days post-infection. PTAA treatment started at 28 or 35 DIV resulted in an 
amount of PK-resistant material that was similar or lower than at the time of treatment start 
and further indicates that PTAA interferes with prion replication within the tissue and 
possibly transforms pre-existing prions into a form that is less efficiently detected. It is not 
clear, however, how this anti-prion seeding effect is achieved.  
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OUTLOOK 
 
The established ELISA assay has been validated for the detection of PrPC and PrPSc in cell 
lysates and in extracts of brain tissue cultures. Discrimnation of both isoforms was done by 
PK digestion. This method also enables the determination of total PrP concentractions by 
subtracting PK digested from non-digested samples. However, the PrP ELISA has some 
automation but no high-throughput potential because of the following reasons: solid phase 
ELISA requires washing steps and is normally performed in 96-well plates. 
Therefore, I used the data obtained from the ELISA experiments as basis to develop 
homogeneous phase TR-FRET assays which are amenable for automated high-throughput 
applications because they are running in 384-well plates obviating washing steps. 
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PART II RESULTS 
PrP Time-Resolved Fluorescence Resonance Energy Transfer Assays 
 
Overview of FRET-Based PrP Assays 
In order to establish a FRET-based PrP assay I utilized the LANCE technology developed by 
PerkinElmer [www.perkinelmer.com/LANCE] as well as the Ruthenium-based system 
introduced by Roche [www.roche-diagnostics.ch]. In homogeneous phase FRET technologies 
of the LANCE format, one PrP-directed POM antibody is conjugated with the donor 
fluorophore Europium chelate (Eu), whereas the other POM antibody is labelled with an 
acceptor fluorophore allophycocyanin (APC) [Kronick, 1986]. When Eu and APC are in close 
proximity by virtue of the biomolecular interaction, a fluorescence resonance energy transfer 
(FRET) is detectable upon fluorescence emission of APC. The level of light emitted from the 
acceptor fluorophore is proportional to the degree of donor-acceptor complex formation. I 
established different PrP FRET-based assays which are summarized in Figure 18a-c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18.  Overview of FRET-based PrP assays 
Model systems used for PrP FRET detection assays. The POM antibody library allows the versatile tagging of 
PrP either at its N- or C-terminal region or at both termini simultaneously. Two POM antibodies conjugated with 
Eu and APC, respectively, were used to generate a FRET signal if the tandem pair is in close proximity. Finally, 
the energy transfer of Europium chelate-labelled POM antibody to APC-labelled POM antibody is evaluated in a 
HTRF (without washing) and/or TR-FRET (after washing) mode. Different types of PrP-based FRET assays 
were established. a) Detection and manipulation of recPrP, PrPC and PrPSc by HTRF/TR-FRET b) Detection and 
manipulation of PrPC expression on the surface of intact cells by HTRF/TR-FRET. c) Measurement and 
manipulation of PrPC’s endocytosis by HTRF/TR-FRET. 
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FRET Calculation and Parameters 
The Wallac EnVision multilabel reader (PerkinElmer) was applied for all FRET experiments 
using protocols installed by the manufacturer. A nitrogen laser device with an excitation pulse 
of 337.1 nm excites Europium (Eu), which activates APC in a distance-dependent manner. 
Fluorescence emissions are monitored both at 615 nm for Eu and at 665 nm for 
allophycocyanin (APC). The collected fluorescence data is corrected by both background and 
spectral overlap between Eu and APC channel. The resulting Net FRET signal is the number 
of APC counts depending on FRET events. Each well is calculated as: 
 
 
 
 
 
 
 
 
 
Various measurement conditions affect the signal and were tested, including integration time, 
time delay, measurement height as well as different types of plates suitable for FRET 
applications. For all PrP time-resolved (TR) FRET measurements, an integration time of 100 
or the standard 400 µs were used after a time delay ranging from 50 to 100 µs. Depending on 
assay format, FRET parameters such as time delay and integration time are mentioned in each 
set of experiments.  
 
Dynamic Range of the Wallac EnVision Multilabel Reader for Europium Measurements 
In order to determine the dynamic range, sensitivity and precision of the EnVision reader for 
Eu-FRET applications, aqueous solutions of Eu standards were prepared. To increase signal 
intensity, EU standards ranging from 0.1 pM to 10 nM were dissolved in the DELFIA® 
enhancement solution (PerkinElmer Life Sciences) (Fig. 19a). For the measurement settings, I 
employed 100 flashes over 400 µs at 100% light intensity using a 100 µs time delay after each 
flash. The fluorescence emission intensity increased with approximately linear correlation (R2 
= 0.9993) to the Europium concentration ranging from 0.1 to 100 pM (Fig. 19b). The 
coefficients of variation (CV) for the triplicate measurements were below 7% for all measured 
concentrations. The CV is a normalized measure of sample dispersion and therefore a term of 
 
 
 
 
 
 
 
counts  raw counts in APC and Eu channel 
APC blank all reagents except Eu in APC channel 
Eu blank all reagents except APC in APC and Eu channel 
buffer  all reagents except APC and Eu in APC and Eu channel 
P  proportionality factor which defines spectral overlap compensation of FRET results 
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pipetting accuracy. CV values lower than 20% are acceptable. By preparing a clear 96-well 
plate with six different concentrations of Europium in the DELFIA® enhancement solution 
from 0 to 1 pM, I obtained a limit of detection (LOD) for Eu3+ of 0.05 pM (Fig. 19c). The Eu 
standard measurements were also used to calculate the molarity of Eu-coupled biomolecules 
(see below). 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Dynamic range of the Wallac EnVision multilabel reader for Eu3+ chelate 
A Eu standard solution was diluted to the indicated concentrations in the DELFIA® enhancement solution. In a 
clear 96-well plate, 200 µl per well of the indicated Europium solution was manually pipetted in triplicates. The 
fluorescence was measured at 615 nm. (a) This figure shows the dynamic range of the Envision reader from 10-6 
to 104 pM Eu3+. The sigmoidal regression curve (in red) gives a R2 value of 0.9994. (b) A linear correlation (R2 
= 0.9993) to the Eu concentration ranging from 0.1 to 100 pM was found. The limit of detection (LOD) of 
Europium standard is 0.05 pM. Shown are standard deviations of triplicates. 
 
Measurement Time of the Wallac EnVision Multilabel Reader and Signal Stability 
The Wallac EnVision multilabel reader combines standard FRET technology with time-
resolved (TR) measurement of long-lived fluorescence. By introducing a time delay between 
excitation and fluorescence measurement, this technique allows the clearance of all non-
specific short-lived background fluorescence. This is shown in Fig. 20a. For the EnVision 
reader the overall measurement time is the sum of the plate transports (in and out), the 
exposure time and the time window. For a 50 µs exposure time and a time window of 100 µs 
per 96-well plate this adds up to 65 s. The exposure time settings are typical instrument 
settings as recommended by the device manufacturers for average HTS applications. 
Moreover, the specific signal over background net FRET signal generated remains detectable 
for at least 48h when the plate is stored at 4°C (Fig. 20b). 
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Figure 20. Time Delay and Stability of the FRET signal 
(a) Detection of Eu standard solution with TR fluorescence measurement. Eu standard solution from 0 to 1 pM 
was pipetted into a clear 96-well plate. This plate was measured for three different time delays. The time window 
was kept constant. (b) To test FRET signal stability over time, serially diluted recPrP ranging from 0 to 100 
ng/ml was detected by the FRET antibody combination POM1Eu/POM19APC and measured at day 0 (t=0 h), 
day 1 (t=24 h) and day 2 (t=48 h). 
Preparation and Characterization of FRET Antibody Tandem Pairs 
 
Based on the goal to detect PrP via a homogeneous FRET immunoassay, several POM 
antibodies (POM1, 2, 3, 5, 6, 7, 10, 11, 15, and 19) as well as the antibody 3F4, which is an 
antibody directed against the amino acids 109-112 of the human prion protein [Bolton et al., 
1991], were coupled either to the donor fluorophore Eu or to the acceptor fluorophore APC. 
In Fig 21, the coupling steps are exemplarily shown for POM1-Eu and POM19-APC. Native 
full length POM antibodies were dialyzed in Eu or APC coupling buffer, respectively, at 4°C 
over night. In preliminary experiments, POM antibodies were conjugated with a 4 or 1.5x 
molar excess of fluorophore, respectively. In a later set of experiments, the molar excess of 
Europium was increased for all coupling reactions from 10x to finally 24x to achieve a higher 
Eu3+/antibody ratio. APC was constantly kept at a 1.5x molar excess to POM antibodies. 
Removal of uncoupled Eu chelate or APC was done either by size exclusion chromatography 
(SEC) (Fig. 21a) or Protein G column, respectively. Purity of conjugated antibodies was 
assessed by Coomassie gels for all labelled antibodies (Fig. 21a and Fig. 21d).        
The absorbance of APC-coupled antibodies was routinely monitored by Nanodrop 
measurements at a wavelength of 650 nm (Fig. 21c). Protein concentration was assessed at a 
wavelength of 280 nm (Fig. 21c). To determine the molarity of POM1-Eu conjugates, 
antibodies were pre-incubated with 0.1 M HCl for 10 min to liberate Europium from the 
antibody and compared to a Eu standard curve according to the manufacturer guideline (not 
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shown). POM antibodies with a good labelling ratio of Eu3+/IgG of 6-7 and APC/IgG of 1.5 
were used in FRET experiments. 
                                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 21. Conjugation of POM1 with Europium chelate and POM19 with APC 
(a) Elution profile of Eu-coupled POM1 antibodies separated by SEC. UV light at A280nm (blue curve) and A215nm 
(red curve) monitor the fractionation. The peak after 12 ml elution volume contains labelled POM1Eu 
antibodies, the smaller peak arising after 22.5 ml elution buffer represents the free Eu chelate. (b) Fractions 
containing POM1Eu and eluate (#E9) were collected and equal volumes of protein were loaded onto a 
Coomassie gel in the presence of β-mercaptoethanol (βME) (reducing conditions). Samples only containing Eu-
conjugated POM1 were pooled and used for experiments. As control, native POM1 was used. (c) Shown is the 
absorbance at 280 nm (black curve) and at 650 nm for APC (red curve) for each POM19APC fraction. (d) Equal 
volumes of fractions (#1-6) containing APC-labelled POM19 antibodies from the Protein G column purification 
step were loaded onto a Coomassie gel under reducing conditions. M: protein marker in kDa. Experiments in 
Fig. (a), (b) and (d) were performed by Rita Moos and Irina Abakumova. 
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Development of a Homogeneous recPrP TR-FRET Assay 
 
In the LANCE format, the fluorescence emissions of the Eu chelate (615 nm) and APC (665 
nm) are measured separately in two steps. The suitability of the EnVision for LANCE 
measurements was tested in the following two biological assay setups: First, a FRET system 
was established to detect recPrP in solution using POM antibodies conjugated either with Eu 
or APC. 
To estimate the dynamic range and sensitivity of the Wallac EnVision multilabel reader for 
complexes between recPrP and FRET antibody pairs, recPrP was 1:1 diluted in Hpl PrP KO 
cell lysate at a starting concentration of 128 ng/ml. Hpl PrP KO cell lysate was used as blank. 
Different FRET antibody pairs were tested. The best results were found with the POM1-
Eu/POM2-APC FRET antibody pair (Fig. 22). The LOD gave a value of less than 100 pg/ml 
recPrP. It seems that a concentration higher than 100 ng/ml recPrP reaches a saturation 
plateau. Excellent S/N ratios as well as Z’ factors were found (Table 5). Therefore, the 
EnVision supported a robust HTS-suitable format for recPrP (Z’ value of above 0.5) with a 
POM1-Eu concentration of 2.5 nM combined with 5 nM POM2APC.   
 
 
  
 
 
 
Figure 22. Titration of monomeric recPrP, LOD, dynamic and linear range 
(a) RecPrP was serially diluted 1:1 in PrP-deficient Hpl cell lysate (BLANK). Net FRET signal was detected 
with 2.5 nM POM1Eu and 5nM POM2APC in 1x LANCE® buffer. Shown are means ± standard deviations 
from hexaplicates. (b) Linearity of FRET signal to analyte concentration was found in the range of 0-100 ng/ml 
recPrP with the POM1Eu/POM19APC FRET antibody pair. 
 
 
 
 
Table 5. FRET assay performance for recPrP detection 
Coefficient of variance (%CV) shows the extent of variability in relation to the mean of the samples. A %CV 
value lower than 20 is acceptable. The signal to noise (S/N) ratio indicates the potential sensitivity of the assay. 
Values higher than 20 are not unusual in FRET assays of the LANCE® format. The Z factor (Z’) is another 
important indicator of assay variability. Values higher than 0.5 are necessary for high throughput applications. 
 
recPrP [ng/ml] BLANK 0.125 0.25 0.5 1,00 2,00 4,00 8,00 16,00 32,00 64,00 128,00 
%CV 13,24 24,74 12,20 8,14 33,31 11,41 4,70 9,55 6,86 2,14 5,28 8,16 
S/N  3,72 7,66 11,67 2,89 8,52 20,79 10,32 14,41 46,32 18,73 12,16 
z'  0,90 0,95 0,96 0,76 0,90 0,94 0,86 0,89 0,96 0,91 0,85 
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To further validate the recPrP-based TR-FRET assay, various other experiments were 
addressed to characterize this assay in more detail. Enzymatic digestion of recPrP with PK is 
shown in Fig. 23a. A constant amount of 100 ng/ml monomeric recPrP was incubated with 
PK in the range of 0 to 2.5 µg/ml PK. A clear decrease in FRET signal intensity dependent on 
increasing PK concentrations was found. As a negative control and to determine the 
background of the assay, PrP-deficient Hpl cell lysate was utilized. Similar results were found 
for tryptic digestion (not shown). In another approach, a constant amount of recPrP was pre-
incubated with different concentrations of unlabelled full length POM1 and POM19 antibody. 
FRET signal was detected with the POM1Eu/POM19APC FRET antibody pair. The higher 
the concentration of the blocking antibodies, the lower the FRET signal. As control, 
unlabelled full length POM2 was used, which had a minor effect on the FRET signal intensity 
(Fig. 23b). In a next experiment, recPrP was pre-incubated with either full length or single 
chain POM2 antibodies at various concentrations. Single chain POM2 antibody weakly 
interfered with the FRET signal upon POM1Eu/POM19APC labelling compared to full length 
POM2 (Fig. 23c), presumably because of less steric interactions.  
 
 
 
 
 
 
Figure 23. Characterization of biochemical recPrP TR-FRET assay 
(a) RecPrP`s PK sensitivity is shown. A constant concentration of 100 ng/ml recPrP was digested with an 
increasing concentration of PK at 37°C for 30 min. Inactivation of PK was done by heating at 95°C for 5 min. 
PrP-deficient Hpl cell lysate was used as negative control. (b) By pre-incubating a constant amount of recPrP 
with different concentrations of unlabelled full length antibodies, either POM1 or POM19, the FRET signal was 
dose-dependent blocked upon addition of the FRET antibody pair POM1Eu/POM19APC. In a control 
experiment, pre-incubation of unlabelled full length POM2 antibody had only a weak effect on the FRET signal 
when using the same FRET antibody pair for detection. (c) A difference in blocking FRET signal was found 
when comparing unlabelled full length POM2 antibody with unlabelled single chain POM2 antibody.  
 
I was wondering, whether the biochemical recPrP FRET assay could also be applied to 
discriminate between monomeric and fibrillic recPrP. Therefore, I generated fibrillic recPrP in 
the presence of GdnHCl by thermal shaking for 48 h [Apetri et al., 2005]. Monomeric and 
fibrillar recPrP was subjected to proteolytic digestion, either with PK or trypsin. In Fig. 24a, 
PK digested recPrP was detected by the C-terminal POM1Eu/POM19APC FRET pair. No 
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fibrillic recPrP was detectable under these conditions. The same results were found when 
monomeric and fibrillic recPrP was digested with trypsin and detected with the same 
antibodies (Fig. 24b). Aggregated recPrP was only detectable by the N-terminal 
POM2Eu/POM2APC FRET antibodies after trypsin digestion. It seems that trypsin digestion 
loosens the aggregated state or makes buried epitopes accessible and enables the detection of 
recPrP (Fig. 24c). 
 
 
 
 
 
Figure 24. Detection of monomeric and fibrillic recPrP after proteolytic digestion 
Monomeric and fibrillic recPrP detection by (a) POM1Eu/POM19APC after PK or (b) POM1Eu/ POM19APC 
or (c) POM2Eu/POM2APC after trypsin digestion. Shown are standard deviations of biological triplicates. 
 
Development of a Homogeneous PrPC TR-FRET Assay  
 
The most common methods for detection and measuring cellular PrP involve Western blot 
analysis or various types of ELISAs [Kretzschmar et al., 1996]. These are time-consuming 
assays and inherently have a low throughput performance. The sensitivity and efficacy of the 
established biochemical recPrP FRET assay prompted an investigation in more complex 
environments. Therefore, to more directly and rapidly analyse PrP from crude cell lysates and 
brain homogenates, the influence of some detergents on the FRET signal intensity was tested 
in recPrP solutions. TritonX-100 (TX100) and Brj35 had a strong influence on the FRET 
signal intensities at the tested concentrations (Fig 25 a/b). 
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Figure 25. Titration experiments of detergents for cell lysis optimisation (opposite page) 
(a) Titration of TritonX100 (TX100) in a recPrP solution. Detection of PrPC was done either with 
POM2Eu/POM2APC or POM1Eu/POM2APC. (b) Titration of Brj35 in a recPrP solution. Detection of PrPC was 
done either with POM2Eu/POM2APC or POM1Eu/POM2APC 
 
Next, the sensitivity for PrPC detection by FRET technology was determined in spiking 
experiments. PrPC expressing N2a and PrP KO cells were lysed in 50 mM TrisHCl pH 7.4 
and 0.5% TX100 for 60 min on a rotating shaker. Protein concentration was determined by 
Bradford assay. An initial total protein concentration of 1 mg/ml of N2a cell lysate was 
serially diluted 1:1 in 1 mg/ml Hpl cells lysate. PrPC was detected by the 
POM1Eu/POM2APC FRET antibody pair. The detection limit for PrPC was determined at a 
total protein concentration of 16 µg/ml (Fig. 26a). A linear range for PrPC detection of non-
spiked N2a cell lysate was found in the range of 50 to 1000 µg/ml (Fig. 26b). 
 
 
 
 
 
 
 
 
 
Figure 26. Characterization of PrPC-based FRET assay 
(a) Crude N2a cell lysate was serially diluted 1:1 in PrP-deficient Hpl cell lysate (BLANK). Net FRET signal 
was detected by 2.5 nM POM1Eu and 5nM POM2APC diluted in 1x LANCE® buffer. Shown are means ± 
standard deviations from hexaplicates. *: p < 0.05; ***: p < 0.001. In (b), linear correlation (R2 = 0.9917) 
ranging from 0.05 to 1 mg/ml of PrPC to total protein concentration was found. Net FRET signal was detected by 
POM1Eu and POM19APC diluted in 1x LANCE® buffer.  
 
I further validated the homogeneous PrPC FRET assay by performing enzymatic proteolysis 
experiments in order to show the degradation of PrPC. N2a cell lysate was digested with 
different concentrations of PK for 30 min at 37°C. PK was inactivated by heating to 95°C for 
10 min and PrPC levels were monitored by POM1Eu/POM2APC FRET antibodies (Fig 27a). 
In another series of experiments, N2a cell lysate was digested with trypsin and inactivated by 
5 mM PMSF (Fig 27b). Inactivation of trypsin was shown by spiking the samples with recPrP 
for 15 min. PrPC was detected by the POM1Eu/POM2APC FRET pair (Fig. 27c). In both 
proteolysis experiments, PrPC levels decreased as a function of enzyme concentration. To 
confirm that PMSF inactivates the action of trypsin, PrPC was detected from digested N2a cell 
lysate by a FRET antibody pair which binds to trypsin-resistant epitopes at the C-terminus 
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(Fig. 27d). Hpl PrP KO cell lysate was used as a negative control in all experiments. The 
sensitivity and specificity of the cell lysate-based TR-FRET assay was controlled by an 
antibody blocking experiment (Fig. 27e). By pre-incubating crude cell lysate with unlabelled 
holo antibody POM2 (mAB) or single chain POM2 antibodies (scFv), a concentration-
dependent decrease in PrPC signal intensity was found as function of unlabelled antibody after 
labelling with POM2Eu/POM2APC (Fig. 27e), demonstrating the specificity of the 
homogeneous FRET assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Characterization of PrPC-based FRET assay 
To validate the PrPC FRET assay, N2a cell lysate was digested with two different proteinases, PK (a) and trypsin 
(b) - (d). The catalytic activity of both enzymes was inhibited by heating (a) or by addition of the proteinase 
inhibitor PMSF (b) - (d). (e) Blocking of FRET antibody epitopes of crude cell lysate by pre-incubation with full 
length or single chain unlabelled POM2 antibodies. FRET measurement was done with POM2Eu/POM2APC. 
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Development of a Homogeneous PrPSc TR-FRET Assay 
 
The strategy to discriminate between PrPC and PrPSc from unfractionated cell lysates and 
brain homogenates is done by enzymatic proteolysis and is outlined in Fig. 28. The gold 
standard procedure to discriminate between both PrP isoforms is PK digestion, which 
completely degrades PrPC, but patially PrPSc. However, other proteolytic enzymes, such as 
trypsin [Yam et al., 2010], can also be used for discrimination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Overview of PrP’s domains, size, digestion fragments and POM antibody binding sites 
The unstructured N-terminal domain of PrP consists of an octarepeat region. The structured C-terminal domain 
contains the sequence for the GPI anchor. Both regions contain post-translational glycosylation sites. The 
numbers describe the position of the amino acids (AA). The proteinase K (PK) and trypsin resistant cores of 
PrPSc are shown. The epitopes recognized by the POM antibodies are also indicated. SP signal peptide, CC 
charged cluster, OR octarepeat, HC hydrophobic core. 
 
 
In order to discriminate between both PrP isoforms, I performed PK titration experiments 
starting from 0 to 32 µg/ml and used the same dilution (10-3 equal 0.01% [lab nomenclature]) 
for all samples (Fig. 29a and b). PK action was halted by 2 mM PMSF. As control, PrP KO 
BH as well as non-digested CD1 BH was used. Results in Fig. 29a and b showed a PK 
concentration-dependent decrease of FRET signals in CD1 and 22L samples after 
POM1Eu/19APC detection, respectively. In a follow up experiment, different dilutions of 22L 
BH from 10-2 to 10-5 was applied to a constant concentration of PK. Only a very high 
concentration of 10-2 diluted 22L BH, PrPSc could significantly discriminated by PK digestion 
from PrP knockout samples (PrP -/-) (Fig. 29c).  
CC1
α1 α3α2
GPI
(Stahl 1987)
1      23  32 51 94   114                                 121      134       150                       200            231
SP Octarepeat (OR) CC2 HC
AA
Domain
α1 α3α2
GPI
α1 α3α2
GPI
trypsin digestionPK digestion
PrPSc
α1 α3α2
GPIPrPC
POM2 POM2POM1 POM1POM3 POM3POM19 POM19
Cathepsin D
PLPC
 
PART II                                                                                                                     RESULTS                                                                         
___________________________________________________________________________ 
 62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Detection of PrPSc in BH after PK digestion 
 Shown are PK titration experiments of non-infected (CD1) (a) and prion-infected (22L) BH (b). PrP KO (-/-) BH 
was used as negative control. Samples were digested for 30’ at 37°C during shaking. PK was inactivated with 
2mM PMSF for 10’ at RT during shaking. FRET detection was done with POM1Eu/POM19APC. Shown are 
triplicates. (c) Different dilution of 22L BH was subjected to a constant concentration of 32 µg/ml PK for 30’ at 
37°C. PK was inactivated with 2 mM PMSF and detected with POM1Eu and POM19APC. Shown are 
decuplicates. **: p < 0.01. 
 
In contrast to PrPC, the immunoreactivity of PrPSc is improved by denaturation, because 
buried epitopes become accessible [Serban D 1990]. To exclude interactions of 
denaturation/neutralisation agents with FRET antibodies, recPrP was added to different ratios 
of denaturation/neutralisation buffer for 10’ at RT and labelled with POM1Eu/POM19APC. 
As summarized in Fig. 30a, 0.1 N NaOH pH 12.3 or 0.3 M NaH2PO4 pH 4.3 completely 
diminished the FRET signal intensity, compared to a ratio of 3/2 of 0.1 N NaOH/ 0.3 M 
NaH2PO4 which had only a marginal effect on the FRET signal intensity. This ratio was used 
to denature PrPSc in further experiments. The use of GdnSCN was not successful (Fig. 30b). 
With these findings, I next used crude brain homogenate (10-3) infected with 22L prions and 
denatured/neutralised with different concentrations of NaOH and NaH2PO4. Here, total PrP 
was determined without discrimination of PrPC and PrPSc. Compared to untreated BH, a 1:1 
ratio of denaturation/neutralisation with  0.1 N NaOH and 0.3 M NaH2PO4 almost doubles 
FRET signal intensity (Fig. 30c). 
 
 
 
 
 
Figure 30. Denaturation of 22L prions (opposite page) 
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(a) RecPrP, pre-labelled with POM1Eu/POM19APC, was exposed to different ratios of 0.1 M NaOH and 0.3 M 
NaH2PO4. Shown are triplicates ± SD. (b) The same experiment was performed with different ratios of 3M 
GdnSCN and 0.1 M NaHCO3. Shown are triplicates ± SD. (c) Prion-infected BH (22L) was diluted to 10-3 and 
exposed to 0.1 N NaOH for 10 min at room temperature during shaking (750 rpm). The action of NaOH was 
neutralised with 0.3 M NaH2PO4. Detection was done with POM19Eu/POM1APC. Time delay/window: 100 
µs/400 µs. Shown are 15-plicates. 
 
To determine the limit of detection of PrPSc, 10% brain homogenates of 22L prion infected 
mice were prepared and serially diluted 1:10 in PrP KO brain homogenate. PrPSc levels were 
determined after PK digestion and denaturation with the POM1Eu/POM19APC FRET 
antibody pair. PrPSc was detectable at a brain homogenate dilution of 10-5 (Fig. 31). 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. PrPSc detection in 22L-infected murine brain homogenates  
 
PrPSc was detected after proteolytic digestion with PK, denaturation with 0.1 N NaOH and neutralization with 
0.3 M NaH2PO4. PrP WT CD1 brain homogenate was used as control. A prion titer of 10-5 was detectable. *: p < 
0.05. PrP -/- : PrP knock out brain homogenate. 
 
Development of a Heterogeneous PrPC Cell Surface TR-FRET Assay 
 
In a first set of experiments I examined whether the FRET assay could be applied to monitor 
the presence of PrPC on the cell surface of living N2a cells. To test this idea, different 
numbers of intact N2a cells were seeded in 96-wells one day before the experiment. For 
FRET detection of PrPC on intact cells, different tandem antibody combinations were used 
and co-incubated in Tris/Krebs buffer at 4°C for 30 min. Fig. 32 a and b illustrates graphs 
showing the cell surface PrPC expression of living N2a cells directly after labelling (Fig. a) or 
after (Fig. b) washing out the non-reactive labelling antibodies as a function of cell number. 
PrP knock-out cells (Hpl PrP KO) lacking expression of PrP were used as negative controls.  
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Figure 32. PrPC detection at the cell surface of living cells as a function of cell number  
Using equimolar mixtures of FRET antibody pair POM2Eu/POM2APC, PrPC was detected as a function of cell 
number before (a) and after (b) a washing step at the surface of intact N2a cells. Hpl PrP KO cells were used as 
negative controls. Mean ± SD are shown from triplicates. K = 1000. 
 
Surprisingly, not all used FRET antibody combinations worked. A correlation of signal-to-
cell number ratio was found for the N-terminal POM2Eu/POM2APC antibody pair, even 
without a washing step. This indicates that the FRET signal generated by the bound 
antibodies is directly proportional to the amount of PrPC expressed on the surface of living 
N2a cells. This also proves that the used antibodies are not degraded or cleaved from the cell 
surface during labelling. The second tested tandem antibody pair, C-terminal directed 
POM1Eu/POM19APC, did not work (not shown). A reason could be that steric hindrances 
interact with their target epitopes and therefore become inaccessible for binding. The 
reduction of the FRET signals before and after the washing step resulted most likely from the 
removal of non-binding antibodies. POM2Eu/POM2APC FRET signals from PrP0/0 Hpl cells 
are negligible and disappear after a washing step with Tris/Krebs buffer. In a further 
experiment, N2a cells were seeded in a 384-well plate from 32’000 to 0 one day before the 
experiment. In Fig. 33a and b, results are shown for the POM2Eu and POM1APC in HTRF 
and TR-FRET mode, respectively. In HTRF mode, a number of 500 cells are clearly 
detectable. The results are even more robust in the TR-FRET mode after removing unbound 
FRET antibodies by washing. For other FRET antibody combinations such as 
POM1Eu/POM2APC and POM2Eu/POM2APC, respectively, less robust results were found 
in the HTRF mode (Fig. 33c and d).  
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Figure 33. Detection of PrPC on the cell surface of living N2a cells  
Cell surface detection of PrPC in the 384-well format. (a) POM2Eu/POM1APC in HTRF and (b) in TR-FRET 
mode. (c) POM1Eu/POM2APC in HTRF and (d) POM2Eu/POM2APC in HTRF mode. Shown are triplicates.  
*: p < 0.05; **: p < 0.01; ***: p < 0.001. 
 
The N-terminal octarepeat of PrP contains four POM2 antibody binding sites [Polymenidou et 
al., 2008]. To prevent a binding preference for either POM2Eu or POM2APC labelled 
antibodies, equimolar concentrations were used in titration experiments (Fig. 34). Briefly, 
20’000 (20K) N2a cells were seeded in 96-wells one day before starting the experiment. 
Equimolar antibody concentrations ranging from 1-17.5 nM were diluted in Tris/Krebs buffer. 
Cell labelling was done at 4°C for 30 min. Immediately after an included washing step with 
Tris/Krebs buffer, FRET signals were measured. Concentrations as low as 2.5 nM for the Eu-
Donor and APC-acceptor POM2 antibody were sufficient to get a large and specific signal for 
each fluorophore on intact N2a cells (Fig. 34a and b). The detected FRET signal reached a 
plateau at about 7.5 nM for each POM2 FRET tandem antibody, suggesting the saturation of 
specific recognition sites of the conjugates (Fig. 34c). 
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Fig. 34. Titration experiments of POM2Eu/POM2APC conjugated antibodies at the surface of living N2a 
cells (opposite page) 
The fluorescence of the donor (POM2Eu) (a) and the fluorescence of the acceptor (POM2APC) (b) were 
measured separately for each channel in the titration experiments. Net FRET signals are shown in (c). Each point 
represents the mean ± SD of sixplicates.  
 
Next, I did binding studies of POM2Eu/POM2APC antibodies at the surface of viable N2a 
cells. For that, an equimolar concentration of 2.5 nM was used for both antibodies. FRET 
signals were measured at different time points directly or after a washing step (Fig. 35). 
Without washes, antibody saturation seems to reach a plateau after 2 hrs, in contrast, FRET 
signals stay constant over the measured time after washing out unbound antibodies. For the 
following experiments, POM2Eu and POM2APC tandem antibodies were used at 2.5 nM 
concentrations and the cell surface labelling procedure was done at 4°C for 30 min. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Binding studies of POM2Eu/POM2APC FRET antibodies on the surface of living N2a cells. 
Binding of the FRET antibody pair was performed at 4°C. One day before, 40’000 N2a cells were plated into 96-
well plates. FRET signals were measured at different time points without and after washing out unbound 
antibodies. Each bar represents the mean ± SD of sixplicates.  
 
Only unspecific FRET signals were observed when cocultering mono-labelled intact N2a and 
Hpl cells in the same wells for 18 hours. Both cell lines were each incubated with both 
POM1-Eu and POM2-APC antibodies, respectively. The coupling procedure was performed 
at 4°C for 30 min. To remove unbound antibodies, the cells were washed two times with pre-
warmed cell culture medium. All possible “Eu-APC”-cell culture combinations were tested 
and Net FRET signals were measured at two different time points t=0 and t=18h (Fig. 36 a 
and b).  
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Figure 36. Mono-labelled cell co-culturing experiments 
For the cell culture experiments, cells were pre-incubated either with POM1-Eu (N2aEu or HplEu) or POM2-
APC antibodies (N2aAPC or HplAPC) at 4°C for 30 min. After removal of unbound antibodies by a washing 
step, 20’000 mono-labelled N2a cells were co-cultured either with 20’000 mono-labelled N2a or Hpl cells. As a 
control experiment, HplEu and HplAPC were cocultured. Net Fret signals were immediately measured after 
plating the cells (t=0) (a) or after 18 hours (b). 
 
Next, I wanted to control the cell surface levels of PrPC pharmacologically. To that aim, N2a 
cells were treated with Brefeldin A (BFA). BFA is a compound that prevents trafficking of 
proteins from the endoplasmatic reticulum to the Golgi apparatus [Nebenfuhr, 2002] and 
downregulates the expression of PrPC at the cell surface. For this experiment, 40’000 N2a 
cells were incubated with different concentrations of BFA in cell culture medium for 18 hrs. 
After washing, FRET signals were detected with equimolar mixtures of POM2Eu/POM2APC 
in Tris/Krebs buffer. Again, the FRET signals are dependent on the number of PrPC at the cell 
surface (Fig. 37). 
 
 
 
 
 
 
 
 
Figure 37. Detection of cell surface PrPC after BFA treatment 
The Figures show a dose-response for BFA treatment in (a) without and in (b) after a washing step. 
 
The release of a protein from intact cells into the medium with phosphatidylinositol 
phospholipase C (PI-PLC) is considered for the presence of a phosphatidyl-inositol-
containing glycolipid anchoring the protein to the cell surface [Low MG, 1987]. PrPC is 
anchored to the cell surface by a GPI glycolipid [Stahl N, 1987] and can be released by PI-
PLC digestion. To extend the cell surface studies, I approached PI-PLC to deplete PrPC from 
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the plasma membrane of intact cells. For that, living N2a cells were digested with increasing 
concentrations of PI-PLC at 4°C for 30 min. Increasing PI-PLC concentrations significantly 
increased PrPC in cell culture media (Fig. 38a), however, a significant PrPC decrease on the 
surface of living N2a cells could not be detected.  These experiments confirm that binding of 
antibody relies on the presence of the extracellular prion protein, such that only cell surface 
protein can be detected.   
 
 
 
 
 
 
 
Figure 38. PI-PLC digestion of living N2a cells 
Digestion of intact N2a cells with PIPLC at 4°C, (a) cleaved PrPC in cell culture media, (b) cell surface 
expression of PrPC.   
 
I was wondering, whether PrPC cell surface detection by different FRET antibody 
combinations depends on a single double-stained PrPC molecule or two or more mono-
labelled PrPC molecules forming a higher molecular complex. For that reason, intact 
POM2Eu/APC FRET-labelled N2a cells were exposed to different detergents, which loosens 
cell membrane structure. Each detergent extremely decreased the FRET signal (Fig. 39), 
assuming that complex membrane structures are mainly responsible for the FRET signal 
rather than single PrPC molecules distributed over the whole cell surface.  
 
 
 
 
 
 
 
 
Figure 39. Membrane disruption of intact FRET-labelled N2a cells  
One day before, 40K N2a cells/well were plated onto a 96-well plate. Next day, the cells were labelled with 2.5 
POM2Eu and 5 nM POM2APC for 30’ at 4°C. After removing non-reactive antibodies, cells were exposed to 
0.5% Brj35, NP40 TritonX100 for 30’ at 4°C. 
Tris/Krebs 0.5% Brj35 0.5% NP40 0.5% TX100 0.5% Tween20 Hpl
0
500
1000
1500
2000
2500
3000
3500
4000
4500
Ne
t F
RE
T
 
0 5 10
0
1000
2000
POM2Eu/POM2APC
POM1Eu/POM2APC
PI-PLC [µg/ml]
N
et
 F
R
ET
  
0 5 10
0
2000
4000
6000
8000
10000
POM2Eu/POM2APC
POM1Eu/POM2APC
PI-PLC [µg/ml]
N
et
 F
R
ET
 
a b 
PART II                                                                                                                     RESULTS                                                                         
___________________________________________________________________________ 
 69 
Interfering PrPC Cell Surface FRET Signals with Prions 
 
According to the “prion-only” hypothesis, PrPSc needs PrPC as a template for its propagation 
[Prusiner, 1982]. I was wondering whether I can show such an interaction by FRET. To do so, 
PrPC of non-infected N2a cells was labelled with POM1Eu/POM19APC or 
POM1Eu/POM2APC FRET antibodies at 4°C and washed with Tris/Krebs buffer. Labelled 
cells were exposed to different concentrations of either prion-infected (RML BH), non-
infected (CD1 BH) or PrP-KO (PrP-/-) brain homogenates. Brain homogenates were diluted in 
cell culture medium and experiments were performed for 30 min at 37°C or in a control 
experiment at 4°C (Fig. 40). Clear differences in FRET signal intensities were detected at 
37°C (Fig. 40a and c) compared to 4°C, where the signals were quite similar (Fig. 40b and 
d). It seems that interactions of PrPC and PrPSc occur at higher temperatures. Differences in 
FRET signal intensities were also observed between the two different FRET antibody 
combinations. Higher FRET signals were observed with the POM1Eu/POM19APC FRET 
antibody pair. An explanation could be that upon binding of PrPSc to PrPC, POM1 and 
POM19 epitopes become closer to each other and therefore the FRET signal is increasing 
(Fig. 40a). Using the POM1Eu/POM2APC FRET antibody pair, a decreasing FRET signal 
was monitored. However, whether conformational changes are responsible for the different 
FRET signals can only be proved when repeating these experiments with purified PrPSc.  
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Figure 40. FRET-PrPC cell surface blocking experiments (opposite page) 
PrPC on the surface of N2a cells was labelled either with POM1Eu/POM19APC (a/b), POM1Eu /POM2APC 
(c/d) or POM2Eu(24x)/POM2APC (not shown). Cells were washed and thereafter exposed to 10-3 or 10-4 in 
OptiMEM diluted brain homogenates (BH). Experiments were performed either at 37°C (a/c) or 4°C (b/d). 
OptiMEM media without any supplements was included as an additional control.         *: p < 0.05; **: p < 0.01; 
***: p < 0.001. 
 
Development of a Heterogeneous PrPC endocytosis TR-FRET Assay 
 
It has been shown that PrPC, located on the cell surface, is constitutively internalised and 
recycles back to the plasma membrane [Harris DA, 2003; Prado MA, 2004] within 60 min 
[Shyng SL, 1993; Harris DA, 2003]. This cycling process is inducible by copper or zinc ions 
[Pauly PC & Harris DA, 1998; Watt NT & Hooper NM, 2003; Lee KS, 2001] and is believed 
to be necessary for conversion of PrPC to PrPSc [Borchelt DR, 1993].  
We therefore wondered whether the FRET technology could also be used to measure PrP’s 
endocytosis. In a first set of experiments, living cells were preincubated only with one of the 
two FRET antibodies at 4°C and thereafter exposed for different time points at 37°C. After 
several washing steps to remove unbound antibodies, the cells were labelled with the second 
FRET antibody at 4°C for 30 min. In a control experiment (no internalization) the same FRET 
antibody pair was used and all incubation times were performed for the same time period but 
at 4°C for 30 min. Low temperature prevents all energy-driven internalization processes 
[Goldenthal K, 1984] and only a marginal amount of PrPC became endocytosed at 4°C. 
Incubation at 37°C led to a decrease in cell surface PrPC expression, presumably because of 
internalisation (Fig. 41). 
 
 
 
 
 
 
 
 
Figure 41. Kinetics of PrPC on intact murine N2a cells 
N2a cells were incubated with POM1Eu at 4°C for 30 min, washed and exposed to 37°C for various time points 
in cell culture medium. After each time point, POM2APC was added and the FRETsignal was measured. To 
block endocytosis of PrPC, all steps were performed at 4°C. 
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PrPC Cell Surface Detection of Human Cells with TR-FRET 
 
Next, we decided, in collaboration with Prisca Liberali and Lucas Pelkmans (Institute of 
Molecular Life Sciences, University of Zürich), to elucidate genes involved in the endocytosis 
of human PrPC in cells. This should be done with a treatment of siRNAs which interfere with 
the expression of specific genes with complementary nucleotide sequence [Elbashir et al., 
2001]. To monitor toxic effects of siRNA treatments, an alamarBlue viability assay was 
established. 
 
AlamarBlue Cell Viability Assay 
AlamarBlue is the commercial trademark of resazurin which is used as an indicator of cell 
viability in mammalian cell cultures [Anoopkumar-Dukie et al., 2005]. It is a blue dye, itself 
weakly fluorescent until it is irreversibly reduced to the pink colored and highly red 
fluorescent resorufin [Bueno C et al., 2002]. To assess whether the alamarBlue assay could be 
used to monitor the cell viability of cells, cell titration experiments were performed. One day 
before the start of the experiment, different numbers of N2a cells ranging from 32’000 to 0 
were plated into a 384 well plate. Cells were incubated for 12 h with alamarBlue and the 
fluorescent signal was read with a Paradigm fluorescent reader. The fluorescent signal 
depends on the number of living cells (Fig. 42a). In the same experiment the cell surface 
expression of PrPC was determined by FRET. A good correlation of cell viability versus cell 
surface PrPC expression was found (Fig. 42 insert). I used HeLa cells to do a time course 
analysis. Different amounts of cells were cultured for three days and after each day, the 
viability was measured (Fig. 42b-d). Cell death was induced by co-culturing HeLa cells with 
staurosporine (STS), a compound that activates caspase-3 [Chae et al., 2000] (Fig. 42e-g). 
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Figure 42. AlamarBlue viability assay (opposite page) 
Viability of HeLa and Hpl PrP KO cells was monitored over three days, (a) day one (b) day two (c) day three.  
Induction of cell death by Staurosporine treatment for six hours (d) and at a concentration of 2.5 µM over six 
hours. In (e) is shown the summary of STS treatment. AU: Arbitrary Units. 
 
PrPC Cell Surface Detection of Intact Human Cells with TR-FRET  
I tried to detect PrPC on the surface of two different human cell lines, namely HeLa and A549 
(lung epithelial cells) cells. Best results from FRET antibody titration experiments revealed, 
that POM antibodies with binding epitopes in or near the N-terminal region of PrPC could be 
used either as donor or acceptor FRET antibody in both cell lines (Fig. 43). Routinely, I 
utilized POM2Eu as donor FRET antibody, because POM2’s four binding epitopes at the N-
terminal region of PrPC generated higher FRET signals compared to other members of the 
POM antibody family, especially in low PrPC expressing cells. 
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Figure 43. Best POM antibody pair analysis for PrPC cell surface detection by solid phase FRET (opposite 
page) 
Various FRET antibody combinations were tested for detection of PrPC on the cell surface of living A549 cells. 
APC-coupled POM2 antibody (2APC) was used as FRET acceptor molecule for all experiments. Various POM 
antibodies (POM1, 2, 3, 5, 6, 7, 11, 15) were coupled to Eu and tested. Shown are results from hexaplicates ± SD 
in the HTRF mode (100 µs time delay; 400 µs time window).  
 
Additionally, PrPC expression levels of HeLa and A549 cells were confirmed by ELISA 
experiments (Figure 44). The highest OD signals of PrPC were achieved when using the 
POM2/POM2 antibody combination (Fig. 44a), followed by the POM2/POM11 (Fig. 44b) 
and POM11/POM2 (Fig. 44c) antibody pair. The POM11/POM11 ELISA experiment had the 
lowest OD values, presumably because only two POM11 binding epitops are available (Fig. 
44d). A549 cells contain about 1.5 ng/ml PrPC in 100 µg/ml crude cell lysate and have similar 
PrPC levels as murine N2a cells. These results were confirmed by all four different ELISA 
experiments. HeLa cells express PrPC less than nine times compared to A549 cells and N2a 
cells. 
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Figure 44. Detection of PrPC in HeLa and A549 cell lysates by sandwich ELISA 
PrPC expression levels were determined by four different ELISAs. Plates were coated either with POM2 or 
POM11 antibody and detected with either biotinylated (bio) POM2 or POM11 antibody. In (a) POM2/POM2bio, 
(b) POM2/POM11bio, (c) POM11/POM2bio (d) POM11/POM11. Shown are results from triplicates. 
 
I further characterized the POM2/POM2 antibody combination in ELISA and FRET 
experiments. In ELISA experiments, either full length recPrP (Fig. 45a) or brain homogenates 
of NGPI mice (∆141-225) (Fig. 45b) was used to validate the POM2/POM2 specificity. In 
both ELISA experiments the POM2/POM2 ELISA antibody pair enabled the detection of PrP. 
In FRET experiments, the N1-fragment of recPrP (residues 23-111) was used (Fig. 45c). As 
positive controls, the POM2Eu/POM2APC and as a negative control the 
POM1Eu/POM2APC FRET antibody pair was utilized. The N1-fragment was detectable with 
the POM2Eu/POM2APC antibody pair but not with the POM1Eu/POM2APC pair, because 
the POM1 epitope is not present within the N1-fragment of PrP. 
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Figure 45. POM2/POM2 ELISA and homogeneous FRET experiments (opposite page) 
The specificity of PrP detection by the POM2/POM2 antibody pair is shown by ELISA experiments, in (a) 
recPrP spiked in Hpl PrP KO cell lysate and in (b) brain homogenates from different ages (day68 to day76) of 
N-GPI mice. Shown is the mean of triplicates. (c) The corresponding FRET experiment was done with 
recombinant PrP N1-fragment. As negative control, the POM1Eu/POM2APC pair was used. Shown are 
hexaplicates. 
 
Based on these results, I focused in more detail on the POM2Eu and POM2APC FRET 
antibody pair (2Eu/APC). To verify 2Eu/APC, cell titration experiments were performed. 
Different amounts of Hela cells were plated one day before in 384-well plates (Fig. 46). Hpl 
PrP KO cells were used as negative control. A cell number dependent FRET signal was 
detected. A linear correlation of the dynamic range was found in the HTRF mode from 0 to 
8000 cells (R2 = 0.92) and a slightly better one in the TR-FRET mode (R2 = 0.98). The 
2Eu/APC FRET pair enables PrPC cell surface detection for 500 HeLa cells in both 
measurement modes. The higher FRET signals measured in the HTRF mode may be due to a 
saturated state of the FRET antibodies which disappears after a washing step in the TR-FRET 
mode. The assay performances are summarized below. The coefficients of variation (%CV) as 
well as the signal-to-noise (S/N) ratio and the Z’ factor are better in the HTRF mode 
compared to the TR-FRET mode. This is most likely due to the washing step in the TR-FRET 
mode. 
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Figure 46. PrPC cell surface detection on HeLa cells by solid-phase FRET 
The specificity of human PrPC detection in living HeLa cells by 2Eu/2APC FRET antibody pair is shown in a 
cell number titration experiment. (a) HTRF mode and (b) TR-FRET mode. *: p < 0.05; **: p < 0.01; ***: p < 
0.001. 
 
Similar results were found for the A549 cell titration experiments using the 
POM2Eu/POM2APC FRET antibody combination (Fig. 47).  
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Figure 47. PrPC cell surface detection on A549 cells by solid-phase FRET (opposite page) 
The specificity of human PrPC detection in living A549 cells by 2Eu/2APC FRET antibody pair is shown in a 
cell number titration experiment. (a) HTRF mode and (b) TR-FRET mode. *: p < 0.05; **: p < 0.01; ***: p < 
0.001. 
 
In the next experiments, PrPC cell surface detection with 2Eu/APC was further validated. 
First, a blocking experiment was performed. A constant amount of intact HeLa cells was pre-
incubated with different concentrations of unlabeled holo POM2 antibody for 30 min at 4°C. 
After removal of unbound antibodies by a washing step, the cells were labelled with 2Eu/APC 
for 30 min at 4°C. Results in the HTRF and TR-FRET mode showed an increase of FRET 
intensity with decreasing POM2 concentrations (Fig. 48a and b). In Fig. 48c and d, HeLa 
cells were first labelled with 2Eu/APC and then exposed to trypsin digestion for 30 min at 
37°C. Shown are results before digest and thereafter in the HTRF and TR-FRET mode. In the 
presence of trypsin, no FRET signal was detectable. Next, GPI-anchored PrPC was removed 
by different concentrations of PI-PLC. A549 cells were first labelled with 2Eu/2APC (Fig. 
48f) and then digested with PI-PLC for 30 min at 4°C. The supernatant was transferred into a 
new plate and incubated with the POM2Eu/POM2APC for 30 min at 4°C. PI-PLC digestion 
leads to a dose-dependent reduction of PrPC on the surface of A549 cells and to an increase in 
the medium (Fig. 48g and h). PI-PLC treatment had no effect on viability of A549 cells (Fig. 
48i).  
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Figure 48. POM2/POM2 ELISA and FRET experiments 
The specificity of PrPC detection by 2Eu/APC is shown by a blocking experiment with unlabelled POM2 in (a) 
in the HTRF and (b) in TR-FRET mode. Trypsin digestion is shown in (c-e). PI-PLC digestion of A549 cells is 
shown in (f-h). In (f) FRET signals before PI-PLC digestion. In (g) accumulation of cleaved PrPC in the 
supernatant and in (h) the PrPC level on the cell surface after PI-PLC treatment. (i) Viability was monitored by 
the alamarBlue assay. AU: Arbitrary Units. 
 
Pharmacological manipulation of the PrPC expression level at the surface of living HeLa or 
A549 cells was done with BFA treatment (Fig. 49a and Fig. 49b). Potential toxic effects of 
BFA were monitored by the alamarBlue assay. A BFA concentration of 1 µg/ml had no effect 
on the viability of A549 cells and decreased the expression of PrPC at the cell surface (Fig. 
49c). 
 
 
 
 
 
 
Figure 49. Manipulation of PrPC cell surface expression by BFA treatment 
One day before the experiment, 4000 HeLa cells were seeded into a 384-well plate. Cells were treated with 
different concentrations of BFA for 18 hours at 37°C. BFA was removed and one part of the plate was used for 
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the 2Eu/APC cell surface FRET experiments. The other part of the plate was used for the alamarBlue assay, 
measured 24h after BFA treatment. (a) HTRF mode, (b) TR-FRET mode and (c) alamarBlue viability assay. 
BFA was dissolved in DMSO and the concentration was kept constant at 0.75%. AU: Arbitrary Units. 
 
Genetic manipulation of the PrPC expression level at the surface of living A549 cells was 
done with PRNP siRNA treatment (Fig. 50a). Scrambled as well as GAPDH siRNAs were 
used as negative controls additionally to Hpl PrP KO cells. A decrease of PrPC expression 
level on the surface of living A549 cells was found, depending on PRNP siRNA 
concentration. No toxic effects of siRNA were monitored by the alamarBlue assay. To induce 
cell death chlorpromazine (CPZ) was used as control (Fig. 50b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50. Manipulation of PrPC cell surface expression by siRNA treatment 
Four days before, 500 A549 cells were seeded into a 384-well plate. Cells were treated with different 
concentrations of PRNP siRNA and control siRNAs for 3 days at 37°C. Cells were labelled with 
POM2Eu/3F4APC. (a) PrPC cell surface expression in HTRF mode, (b) alamarBlue viability assay of siRNA 
treated A549 cells. CPZ: chlorpromazine.  
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PrPC Endocytosis Assay in Human Cells with solid-phase TR-FRET  
 
During establishing the cell surface detection of PrPC by FRET technology, the question arose 
whether this assay could also be used to measure the internalisation of human PrPC. The 
rationale behind the endocytosis assay is to first label the cells with the donor FRET antibody 
(POM2Eu). After removing of unbound antibodies, exposure to 37°C induces the uptake of 
the antibody-labelled PrPC present at the cell surface. By labelling the cells with the acceptor 
FRET antibody (POM2APC) at various time intervals, endocytosis can be monitored over 
time (Fig. 51a). To calculate the endocytosis of PrPC, baseline experiments are performed, 
where both FRET antibodies are simultaneously given to the cells (Fig. 51b). To measure the 
temporal uptake of PrPC, only POM2Eu antibodies are incubated with the cells at 37°C. At 
different time points, POM2APC antibodies are added (Fig. 51c). The temporal decrease in 
FRET intensity is due to endocytosed Eu-labelled PrPC. The endocytosis rate of PrPC (FRET 
τ0 and τ1) is normalized against the basal uptake of PrPC (FRET τ0) and calculated according 
to the formula in Fig. 51d.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51. Experimental protocol and calculation of the endocytosis index of PrPC 
(a) The experimental protocol of the PrPC endocytosis assay takes the advantage that the FRET phenomenon 
occurs in a distance-dependent manner. By the addition of the FRET antibodies separately and at different time 
points, the distance increases in the course of endocytosis which can be monitored by decreasing FRET signal 
intensities. (b) Endocytosis base line experiment. At time point t=0, both donor and acceptor antibodies are 
given simultaneously. (c) Endocytosis experiment. At time point t=0, only the donor FRET antibody is given. 
Over time, PrPC is internalised by the cells. This is detected by decreased FRET signals after addition of the 
acceptor antibody at different time points. (d) Endocytosis index formula. (b-d). By courtesy of A. Aguzzi 2013. 
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In a first set of experiments, different antibody combinations for the FRET endocytosis 
experiments were tested. Good results were found for the FRET antibody combinations 
2Eu/3F4APC and 2Eu/2APC. It is irrelevant whether first the Eu- or APC-labelled antibody is 
added, although slightly higher FRET signals were obtained when the donor antibody was 
added first.  
To calculate the endocytosis index of PrPC, A549 cells were labelled first with 2Eu 
(endocytosis assay) (Fig. 52a and b) or 2Eu/2APC (baseline experiments) (Fig. 52c and d). 
After washing the labelled cells, endocytosis was induced at 37°C in DMEM medium without 
FBS, antibiotics and phenol red to prevent any cross reaction wth the FRET signal. At 
different time points (t=0 to 70 min) 2APC was added. FRET signals were measured directly 
after addition of the last 2APC (Fig. 52a) and a second time after 30 min incubation at 4°C 
(Fig. 52b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52. Kinetics of PrPC internalisation in A549 cells 
(a) and (b) shows the FRET signals in the endocytosis assay without or after 30 min of incubation at 4°C, 
respectively. (c/d) and summarizes the baseline experiments measured the same way as in (a) and (b). (e) 
Kinetics of PrPC endocytosis. Calculated according to formula in Fig. 52d. 
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In the endocytosis assay, the FRET signal is decreasing over time, indicating the uptake of 
PrPC. In baseline experiments, the FRET signal stays constant over the whole time period. An 
explanation could be cross-linking between PrPC molecules at the cell surface by the 
simultaneously binding of 2Eu/APC and therefore preventing internalisation. A half life time 
of about 30 min for cell membrane PrPC was determined which is in line with a previous 
report [Shyng, 1993]. A steady state was reached at about 40 min at 37°C (Fig. 52c). 
To exclude that PrPC is not released from the cell surface by shedding processes, which will 
also result in a decrease of FRET signal intensity over time, I performed a further control 
experiment. A549 cells were labelled with 2Eu for 30 min at 4°C. After washing, cells were 
incubated with DMEM medium without FBS, antibiotics and phenol red for 30 min at 37°C to 
induce endocytosis. Cells were washed an incubated with 100 µg/ml PI-PLC for 30 min at 
4°C. Supernatant with cell surface cleaved PrPC was transferred into a new plate and 3F4APC 
was added to the treated cells as well as into the supernatant for 30 min at 4°C. Results in Fig. 
53a show the cell surface PrPC expression after PI-PLC treatment. A clear decrease in FRET 
signal intensity could be detected in the presence of PI-PLC. No labelled 2Eu-PrPC is released 
into the medium without PI-PLC treatment (Fig. 53b), indicating that no detectable PrPC is 
released by shedding processes from the cell surface. 
 
 
 
 
 
 
 
Figure 53. No detectable PrPC is released from the cell surface by shedding processes 
PI-PLC was used to detect released instead of internalised cell surface expressed PrPC. (a) shows PrPC levels on 
the cell surface of A549 cells in the presence or absence of PI-PLC. (b) summarizes the PI-PLC cleaved PrPC 
levels in the supernatant. No PrPC was detected in the supernatant without PI-PLC digest. **: p < 0.01. 
 
Pharmacological Inhibition of PrPC Endocytosis  
 
To further validate the endocytosis assay, I wanted to inhibit the endocytosis of PrPC. 
Clathrin- as well as lipid-raft-mediated internalisation processes are involved in PrPC uptake. 
In a first set of experiments, sucrose was used as an inhibitor of clathrin-mediated endocytosis 
processes. HeLa cells, labelled with 2Eu, were exposed for 30 min at 37°C in the presence of 
different hypertonic sucrose solutions ranging from 0 to 0.5 M. FRET was measured in HTRF 
and TR-FRET mode after 2APC labelling. Toxic effects of sucrose were monitored by the 
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alamarBlue assay. Sucrose shows a weak effect on inhibition of PrPC uptake in HeLa cells. A 
slightly higher FRET signal was found for a 0.4 M sucrose solution which is in line with the 
literature and is due to the inhibition of clathrin-mediated endocytosis [Sunyach et al. 2003]. 
However, sucrose also influences the viability of HeLa cells in a dose dependent manner (Fig. 
54). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54. Blocking PrPC endocytosis by hypertonic sucrose solutions 
One day before the start of the experiment, 4000 HeLa cells were seeded per well in a 384-well plate. Next day, 
cells were labelled with 2Eu for 30 min at 4°C. Cells were washed once and incubated for 30 min in the presence 
of increasing sucrose concentrations ranging from 0 to 0.5 M. Results are shown in (a) for the HTRF and in (b) 
for TR-FRET mode. Viability of the cells is shown by the alamarBlue assay in (c). Hpl cells were used in control 
experiments. 
 
As an inhibitor for lipid-raft-mediated endocytosis processes, methyl-β-cyclodextrine 
(MβCD) was used. POM2Eu labelled cells were incubated in the presence of decrasing 
MβCD-concentrations ranging from 10 to 0 mM for 30 min at 37°C. FRET was measured in 
HTRF and TR-FRET mode. An inhibitory effect for MβCD was found in a concentration 
range of 1 to 0.1 mM. Toxic effects of MβCD were monitored by the alamarBlue assay (Fig. 
55). 
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Figure 55. Blocking PrPC endocytosis by MβCD 
One day before the start of the experiment, 400 HeLa cells were seeded per well in a 384-well plate. Next day, 
cells were labelled with 2Eu for 30 min at 4°C. Cells were washed once and incubated for 30 min in the presence 
of MβCD ranging from 0 to 10 mM. Results are shown in (a) for the HTRF and in (b) for TR-FRET mode. 
Viability of the cells is shown in (c). Hpl cells were used in control experiments. 
 
To achieve a maximal inhibitory effect of PrPC’s uptake, MβCD and hypertonic sucrose 
solutions were administered at the same time. Cell viability was again measured via the 
alamarBlue assay. Sucrose alone had no effect on PrPC’s endocytosis, but on viability. 
Slightly better was the treatment with MβCD. Best results were found for a mixture of MβCD 
and sucrose which did not influence cell viability (Fig. 56). 
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Figure 56. Blocking PrPC endocytosis by hypertonic sucrose solution and MβCD 
One day before the start of the experiment, 400 HeLa cells were seeded per well in a 384-well plate. Next day, 
cells were labelled with 2Eu for 30 min at 4°C. Cells were washed once and incubated for 30 min in the presence 
of sucrose or MβCD or both together. Results are shown in (a) for the HTRF and in (b) for TR-FRET mode. 
Viability of the cells is shown in (c). Hpl cells were used in control experiment. *: p < 0.05; **: p < 0.01. 
 
Additional experiments were performed in A549 cells. To block clathrin-dependent 
endocytosis processes, chlorpromazine was used (Fig. 57a). A concentration of 1 µg/ml of 
chlorpromazine was sufficient to block endocytosis of PrPC without effecting viability of 
A549 cells (Fig. 57b). Higher concentrations were toxic for the cells. To inhibit raft mediated 
internalisation pathways MβCD was used (Fig. 57c). A concentration of 5 mM MβCD 
blocked endocytosis of PrPC without any toxic effect on cell viability as monitored by the 
alamarBlue assay (Fig. 57d).  
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Figure 57. Blocking PrPC endocytosis by hypertonic sucrose solution and MβCD 
One day before, 400 HeLa cells were seeded per well in a 384-well plate. Next day, cells were labelled with 2Eu 
for 30 min at 4°C. Cells were washed once and incubated for 30 min in the presence of sucrose or MβCD or both 
together. Results are shown in (a) for the HTRF and in (b) for TR-FRET mode. Viability of the cells is shown in 
(c). Hpl cells were used in control experiment. 
 
Inhibition of PrPC Endocytosis by Gene Silencing 
 
Next, I wanted to block the endocytosis of PrPC by siRNA treatment. For that, seven different 
siRNAs were selected which have an impact on endocytosis processes (Tab. 6).  
AP2M1 Encodes the adaptor protein 2 (AP-2) which is involved in clathrin-dependent  endocytosis 
(Boucrot et al., 2010) 
EHD1 Encodes the EH domain-containing protein 1, plays a role in endocytosis (Rainey et al., 
2010) 
GIT2 Encodes the ARF GTPase-activating protein GIT2 (Premont et al., 2004) 
M6PR Encodes the mannose 6-phosphate receptor, interacts with the AP1 clathrin adaptor complex 
(Le Borgne et al., 1997)  
Rab5a G-protein, required for the fusion of  plasma membranes and early endosomes (Gulappa et 
al., 2011) 
VPS28 Encodes the vacuolar protein sorting-associated protein 28 homolog, involved in endosomal 
sorting of cell surface receptors (Bishop et al., 2001) 
VPS35 Encodes the vacuolar sorting-associated protein 35, involved in retrograde transport of 
proteins from endosomes to the trans-Golgi network (Bonifacino & Hurley, 2008) 
Tab. 6. Used siRNAs for gene knockdown  
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All siRNAs were functional and lowered the mRNA expression of the target gene as shown 
by quantitative PCR (Fig. 58a-g). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58. Gene knockdown in A549 cells 
Quantitation of gene silencing in A549 cells treated 3 days with siRNA by real-time PCR for (a) AP2M1, (b) 
EHD1, (c) GIT2, (d) M6PR, (e) PRNP, (f) RAB5a, (g) VPS28 and (h) VPS35. mRNA levels were normalized 
by using GAPDH mRNA. Shown are technical triplicates. 
 
 
The siRNA treatment had no influence on cell viability (Fig. 59a and b). 
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Figure 59. Viability of siRNA treated A549 cells 
A549 cells were treated for three days either with 50 nM (a) or with 10 nM siRNA (b). Cell viability was 
assessed by the alamarBlue assay. Chlorpromazine (CPZ) was used as a positive control for cell death. Shown 
are biological triplicates of siRNA treated cells. 
 
The final experiment was to elucidate genes involved in the endocytosis of PrPC. Two genes, 
AP2M1 and RAB5a strongly blocked the endocytosis of PrPC. Other genes such as M6PR and 
VPS35 had also influence on the internalisationof PrPC, but EHD1 and VPS28 showed no 
effect. Interestingly, GIT2 even enhanced the endocytosis of PrPC. In a control experiment, 
siRNA against the prion protein gene were used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60. Blocking PrPC endocytosis by siRNA treatment and determing the endocytosis index 
A549 cells were treated for three days with 50 nM siRNA and then, the endocytosis assay was performed.  
Shown are hexaplicates. The endocytosis index was calculated for each gene. 
 
Induction of PrPC Endocytosis  
 
Instead of blocking endocytosis, I also wanted to induce the uptake of PrPC at the surface of 
human cells. Copper sulphate (CuSO4) is a known activator of endocytosis of PrPC [Taylor 
2005 and Taylor and Hooper 2007]. 
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In a first set of experiments, HeLa cells were labelled with 2Eu, washed and exposed for 30 
min at 37°C in the presence of CuSO4 solutions with concentrations ranging from 0 to 400 
µM diluted in DMEM cell culture media. In control experiments, CuSO4 was pre-incubated 
with glycine, a known copper chelator, to inhibit the CuSO4–mediated endocytosis of PrPC. In 
both measurement modes (Fig. 61a HTRF and Fig. 61c TR-FRET), a reduction of PrPC at the 
cell surface was measured in the presence of CuSO4. Moreover, addition of the copper 
chelator glycine slowed down the reduction of PrPC at the cell surface. Surprisingly, the 
highest concentration of CuSO4 had no effect on the cell viability (Fig. 61 b and d), but 
glycine stimulated cell metabolism. However, to determine the effect of CuSO4, I performed 
additional control experiments. Copper is assumed to bind at the same region as POM2 
antibodies do. For that reason, I did a solid phase recPrP FRET assay which prevents a 
washing step. Here, recPrP was coated onto a 384-well plate over night and incubated with 
different concentrations of CuSO4. Results showed that CuSO4 interferes with Europium, as 
mentioned by the manufacturer [www.perkinelmer.com/LANCE] as well compete with the 
POM2 antibody for binding sites (Fig. 61e). The Eu/APC FRET endocytosis assay is not 
suitable to measure CuSO4-induced PrP internalisation. 
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Figure 61. Induction of PrPC endocytosis (opposite page) 
CuSO4-induced internalisation of PrPC is shown in the HTRF mode (a) and in TR-FRET mode (c). In control 
experiments, CuSO4 was complexed with glycine. In (c) and (d) the effect of CuSO4 on cell viability is shown. 
(e) Influence of CuSO4 on FRET signal intensity.
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DISCUSSION 
Prion Protein Time-Resolved FRET Assay 
 
To develop a PrP TR-FRET assay, I labelled our in-house anti-prion protein POM antibodies 
with Europium or APC as donor and acceptor fluorophores, respectively. I obtained good 
labelling degrees in the range of 3 to 6 (IgG/Eu) and 1-2 for IgG/APC. The Wallac EnVision 
reader showed an excellent dynamic range (10-6 to 104 pM) and a limit of detection (0.05 pM) 
for Eu3+. These results are in line with the performance being indicated by the manufacturer 
of the Wallac Envision reader [www.perkinelmer.com/LANCE]. 
Recombinant PrP Time-Resolved FRET assay 
 
In this part I tested, whether the POM antibodies enabled the detection of recPrP by time-
resolved FRET in a homogeneous phase. By titration experiments, I identified POM1Eu and 
POM2APC as the best FRET antibody pair to dectect recPrP in Tris/Krebs buffer. This non-
competitive assay displayed excellent Z’ factors, high signal to noise ratios and a very low 
variability. A limit of detection for full length recPrP lower than 0.125 ng/ml was detected in 
spiking experiments with Hpl PrP KO cell lysate which is more sensitive compared to my 
results obtained from ELISA experiments.  
 
In summary, the established recPrP FRET assay is characterized by high sensitivity (LOD < 
125 pg/ml) and specificity (spiking experiments), high-throughput potential (96-/384-well 
format, Z’ factor), fast (within 30 min), the possibility to manipulate the system (enzymatic 
digestion, blocking/binding experiments) and the use of different recPrP variants and FRET-
labelled POM antibody combinations. 
PrPC Time-Resolved FRET Assay 
 
In the next step, I tried to detect PrPC either from murine cell lysates or brain homogenates. A 
LOD of 16 µg/ml N2a cell lysate was obtained. These results differ when comparing with 
human PrPC from cell lysates due to a lower expression level of PrPC. A linear range was 
found for 0 to 1 mg/ml crude N2a cell lysate. In a next set of experiments, cell lysates were 
enzymatically digested with PK or trypsin. In both cases, less PrPC could be detected by 
increasing enzyme concentration. A nice control experiment was shown in the tryptic 
digestion experiment by using FRET antibodies with resistant enzymatic epitopes.  
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In summary, the established PrPC FRET assay in cells and BH has a similar sensitivity as a 
Western blot assay (LOD 16 µg/ml). According to signal-to-noise ratios, high-throughput 
may be possible at the current state, but rather in a 96- than in a 384-well plate format. The 
possibility to manipulate the system (enzymatic digestion, blocking/binding experiments) 
offers some perspectives. However, further optimisation of various parameters (e.g. detergent 
concentration and lysis conditions) is needed to improve the performance of the PrPC FRET 
assay. 
PrPSc Time-Resolved FRET Assay 
 
The discrimination of PrPC and PrPSc was successfully by using PK digestion which 
completely removes PrPC, but not after tryptic proteolysis. After PK digestion, a LOD for 
PrPSc of 0.01% was detected in prion-infected brain homogenate with the C-terminus targeted 
POM1Eu/POM19APC FRET antibody combination. This result was improved by 
denaturation of PrPSc with NaOH to a 10-5 diluted brain homogenate. Here, the SSCA is much 
more sensitive and is able to detect PK-resistant PrPSc in dilutions of 10-9 [Klohn et al., 2003]. 
The detection of PK-resistant PrPSc depends on multiple variables. Although PK is the 
standard method to distinguish between normal and pathological PrP isoforms, prion 
infectivity can be detected in the absence of PK-resistant PrPSc [Lasmezas et al., 1997].  
To improve the performance of the PrPSc FRET assay other proteolytic enzymes could be 
tested to improve the LOD, such as subtilisin [Pilon et al., 2009], chymotrypsin [Pan et al., 
2004], or pepsin [Jackson et al., 2005]. Another important issue is the choice of lysis buffer 
and detergent concentration [Breyer et al., 2012]. It is conceivable that by testing other POM 
antibody pairs, better results can be achevied. 
PrPC Cell Surface Time-Resolved FRET Assay  
 
In a first set of experiments, I tried to detect PrPC at the surface of living N2a cells in a 
homogeneous way (HTRF mode), without removing unbound antibodies. Using different 
Europium- and APC-coupled POM antibodies, I was able to detect PrPC on intact N2a cells in 
a 96- as well as a 384-well-plate format. Best results were found for the POM2Eu/POM1APC 
FRET tandem pair. In N2a cell number titration experiments, a statistical significant result 
was found for 500 N2a cells plated in a 384-well plate one day before. A similar result was 
found for the FRET antibody pair POM1Eu/POM2APC, whereas when using POM2Eu and 
POM2APC a weaker FRET signal was found. 
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In a further set of experiments, the TR-FRET signal was measured after washing out the 
unbound antibodies, as previously shown by others [Maurel et al., 2004]. The TR-FRET 
signal was observed only when using the POM2Eu and POM1APC antibody combination. 
Compared to the TR-FRET assay, the signal intensity measured under HTRF conditions is 
higher, likely because some cells and unbound antibodies are lost during the washing process. 
Surprisingly, the results are statistically stronger in the TR-FRET mode than in the HTRF 
mode. No FRET signal was detected in the TR-FRET mode for PrP-deficient Hpl cells or 
medium only, which clearly demonstrates the specificity of this FRET assay for extracellular 
PrPC epitopes. The FRET signal in the HTRF and TR-FRET mode measured by POM2Eu and 
POM1APC for PrPC was found to be directly proportional to the amount of PrPC proteins at 
the cell surface of N2a cells. A linear correlation was found in the range of 500 to 8000 in the 
HTRF mode and 250 to 8000 in the TR-FRET mode.  
PrPC Endocytosis Time-Resolved FRET Assay 
 
I have studied the endocytosis of endogenously expressed murine and human PrPC on cells in 
vitro. By the addition of the FRET antibodies separately and at different time points, the 
distance between the antibodies increases in the course of endocytosis which can be 
monitored by decreasing FRET signal intensities. A cell surface half life time of about 30 min 
of PrPC could be determined which is in agreement with previous results [Shyng, 1993]. No 
detectable PrPC was found during labelling or endocytosis process in the culture medium, 
confirming that PrPC is mainly endocytosed and not released from the cell surface. In control 
experiments, MβCD and chlorpromazine inhibited endocytosis of PrPC without affecting cell 
viability as reported in earlier publications [Marella et al., 2002; Sarnataro et al., 2009]. 
Next, I wanted to know which genes are involved in the endocytosis of PrPC. For that reason I 
tested several siRNAs which have an influence on the various endocytosis pathways. All 
utilized siRNAs were able to reduce the expression of the target gene on the mRNA level and 
had no implications on cell viability. Among the tested siRNAs, AP2M1 and Rab5a showed a 
stong inhibition of PrPC’s internalisation. AP2M1 codes for the AP-2 adaptor protein which is 
involved in clathrin-dependent endocytosis pathways [Boucrot et al., 2010]. It was shown by 
earlier studies that AP-2 is co-localized in the inner surface of the membrane with PrPC 
[Sunyach et al., 2003]. Rab5a showed even a small increase of the PrPC cell surface 
expression after 30 min and completely blocked the endocytosis of PrPC.  Similar results were 
found by Magalhaes et al., who has shown that green fluorescent protein (GFP)-tagged PrPC 
is endocytosed via Rab5-containing early endosomes, implying a coated pit-dependent uptake 
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of the hybrid protein but not of GPI-GFP [Magalhaes et al., 2002]. Knock-down of the VPS35 
and M6PR also block endocytosis of PrPC but less prominent. Mannose-6-phosphate receptors 
regulate the formation of clathrin-coated vesicles [Le Borgne et al., 1997]. The VPS35 gene 
(vacuolar protein sorting 35 homolog) belongs to a multimeric complex, termed the retromer 
complex which is involved in retrograde transport of proteins from endosomes to the trans-
Golgi network [Bonifacino & Hurley, 2008].  
 
In summary, the FRET-based PrP endocytosis assay can be used as a read-out for the 
efficiency of compounds or small molecules that genetically or pharmacologically block or 
induce PrP endocytosis. It is able to measure the internalisation rate, to characterize the 
different endocytosis pathways as well as to discover genes involved in the uptake of PrP. The 
assay can be performed in 384-well plates and allows high-throughput applications and 
automatisation.  
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OUTLOOK 
 
The time-resolved FRET assay can be applied as novel technical tool to address several 
questions in prion biology and for HTS screening applications. In the following paragraphs are 
some examples described: One question in prion biology concerns genes involved in cell-to-
cell transmission of prions [Aguzzi & Rajendran, 2009]. Answers to this question would be 
helpful in understanding other neurodegenerative diseases such as Alzheimer or Parkinson 
disease which show a similar prion-like spread [Ashe & Aguzzi, 2013; Dunning et al., 2013]. 
To answer this questions the PrPSc FRET assay could be very helpful to study the transmission 
of prions as well as factors determining prion infectivity. 
In a recent publication from our laboratory it could be shown, that antibodies targeting the 
globular domain of PrP induce rapid neurotoxicity in mice and cerebellar organotypic slice 
cultures. Interestingly, deletion in the octapeptide repeats of PrP prevented neurotoxicity of 
globular domain ligands, assuming that the flexible N-terminal part of PrP may exert 
regulatory and executive functions [Sonati et al., 2013]. Here, the FRET-based recPrP assay is 
used in competition experiments to screen for ligands, which bind to the N-terminal part of 
recPrP. Positive hits will be tested in vitro as well as in vivo to prevent globular domain 
ligand-induced neurotoxicity. 
PrPSc needs PrPC to replicate. The PrPC cell surface FRET assay can be used as a screening 
platform. A similar PrP-FRET assay has recently been used for the search of compounds 
which downregulate the expression of PrPC at the cell surface and therefore influence the 
propagation of PrPSc [Karapetyan YE et al., 2013]. Moreover, many interaction partners for 
PrP have been proposed. Here, the PrPC cell surface FRET assay can be used to study 
interactions with other proteins. 
The physiological role of PrPC is unknown. However, PrPC is rapidly internalized from the cell 
membrane and is believed to be involved in a number of cellular processes. How PrPC 
endocytosis influences them in vivo is unknown. The PrPC FRET-based endocytosis assay 
could be used to screen for kinases [Sorkin & Zastrow, 2009] which are involved in the 
internalization of PrPC. This could be helpful to elucidate the physiological function of PrPC 
and to understand the mechanisms involved in prion-induced neurodegeneration [Aguzzi, 
Baumann & Bremer, 2008]. 
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MATERIAL AND METHODS 
 
Mice 
All organotypic cerebellar slice cultures were performed by Ilan Margalith according to Swiss 
federal regulations. The pups used for most experiments were F1 offspring of wt, tga20 or KO 
males on a 129SV/BL background.  
Cell Culture 
PK1 N2a (a subclone of neuroblastoma N2a cells), CAD and Hpl PrP KO cells were cultured 
in 75-cm tissue culture flasks in OptiMeM medium supplemented with 10% (vol/vol) fetal 
bovine serum (FBS) and 1% Pen/Strep. Cells were removed with 2mM EDTA/PBS and split 
1:3 every third day. Human HeLa and A549 cells were cultured in DMEM medium 
supplemented with 10% (vol/vol) fetal bovine serum and 1% Pen/Strep. In FRET 
experiments, all cell lines were cultured in medium without FBS, antibiotics and phenol red. 
To determine cell numbers and viability, resuspended cells were diluted in trypan blue 
solution and counted in a Neubauer counting chamber. 
Preparation of CD1 and RML6 Crude Brain Homogenate 
20% wt/vol RML6 or CD1 brain homogenates in 0.32M sucrose in PBS were prepared by 
three runs in a PreCellys tissue homogenizer with cooling on ice between each run. Protein 
concentrations of RML6 or CD1 brain homogenates were determined using the bicinchoninic 
acid assay (Pierce) and normalized to 1 mg/ml total protein with 0.32M sucrose in PBS. 
Scrapie Cell End-Point Assay of COCSBH 
COCSBH normalized to 1 mg/ml total protein was diluted 1 to 100 fold in cell culture 
medium to obtain a final dilution of 10-4 from full brain. These samples were then serially 
diluted in cell culture medium containing a 10-4 dilution of CD1 BH. Prion-susceptible 
neuroblastoma cells (N2aPK1) were exposed to different COCSBH concentrations ranging 
from 10-4 to 10-9 in a 96-well plate for 3 days. Cells were splitted 3 times 1:3 every second 
day and 3 times 1:10 every third day. Experimental runs comprised 4 plates including a 
COCSBH from six weeks old prion-infected, untreated tissue as a standard plate. The 
infection of N2a-PK1 cells and subsequent processing of the SCEPA were performed as 
previously described (Klohn et al., 2003). Before reaching cell confluence, cells from each 
96-well were filtered onto the membrane of an ELISPOT plate, treated with PK, denatured 
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and PK-resistant PrPSc was detected by immunocytochemistry using alkaline-phosphatase-
conjugated POM1 mouse anti-PrP antibody and alkaline phosphatase conjugate substrate kit 
(BioRad). Samples were quantified by total luminescence per well or in end-point format by 
counting positive wells according to established methods. 
Proteolysis of COCSBH and Western Blot Analysis 
PrPSc was detected by limited proteolysis with proteinase K (PK) (Roche) and analysed by 
Western blotting according to Ilan Margalith’s protocol. 20 µg protein aliquots were digested 
with 25 µg/ml PK in lysis buffer containing 0.5% wt/vol sodium deoxycholate, 0.5% vol/vol 
Nonidet P-40 and 10% vol/vol PBS for 60 min at 37°C and rotating at 700 rpm on a 
thermoshaker in a total volume of 20 µl. This condition allowed specific detection of PrPSc. 
PK digestion was terminated by adding 6.7 µl of 4x LDS loading buffer (NuPAGE, 
Invitrogen) and boiling the samples at 95 °C for 5 min. 20 µl of the samples were separated 
on a 12% Bis-Tris SDS polyacrylamide gel (NuPAGE, Invitrogen) and blotted onto a 
nitrocellulose membrane. Membranes were blocked with 5% wt/vol Topblock (Fluka) in Tris-
buffered saline supplemented with Tween (150 mM NaCl, 10 mM Tris HCl, 0.05% Tween 20 
(vol/vol)) and incubated with POM1 mouse IgG1 antibody to PrPC (anti-PrPC) (200 ng/ml) as 
primary antibody. Horse radish peroxidase (HRP)-conjugated rabbit anti–mouse IgG1 
(1:10,000, Zymed) was used as a secondary antibody. The blots were developed using 
SuperSignal West Pico chemiluminescent substrate (Pierce) and detected in a LAS3000 
system (FUJI). 
ELISA 
For ELISA, COCSBH were diluted ten-fold in TBSTT [50 mM Tris-HCl (pH 7.5)/137 mM 
NaCl/1% Tween20/1% Triton X-100] to obtain a final concentration of 0.1 mg/ml total 
protein. Digestion with proteinase K (PK) was performed in a 96-well plate for 60 min at 37 
°C, rotating at 700 rpm on a thermoshaker in a total volume of 50 µl containing 50 µg ml-1 
PK. Digestion was halted by adding 2 mM phenylmethanesulfonylfluoride (PMSF, 
Calbiochem) and Complete Mini protease inhibitor cocktail (Roche). Digested samples were 
denatured with an equal volume of 3 M GdnSCN for 30 min at 37 °C and diluted with four 
volumes of 0.1 M NaHCO3 pH 8.9. The samples were then detected by sandwich ELISA. 
Briefly, ELISA plates were coated with POM1-antibodies (400 ng/well) in coating buffer 
overnight. After washing with PBST, plates were blocked with blocking buffer (5% TopBlock 
in PBST) for 2 hrs at room temperature. Next, samples were incubated for 2 hours on ELISA 
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plates (Nunc, MaxiSorb). Captured samples were detected with POM19 antibody (1 mg/ml, 1 
hour, diluted in sample buffer) and horse radish peroxidase (HRP)-avidin conjugate (1 mg/ml, 
1 hour, diluted in sample buffer) (BD Pharmingen). Samples were analysed by ELISA in 
technical triplicates and washed five times with PBS 0.05% Tween20 between each antibody 
and conjugate incubations. Finally, TMB substrate (Invitrogen) was added to the wells and 
incubated for 15 min at room temperature and stopped by adding 0.5 M H2SO4. The 
absorbance was read at 450 nm in a VERSAmax microplate reader and validated with the 
SOFTmax PRO software. 
FRET Antibody Labelling 
The monoclonal full length and single chain POM antibodies or recombinant PrP were 
labelled in house for FRET applications. The donor fluorophore was Europium chelate (Eu-
W1024 ITC chelate, AD0096, PerkinElmer). Coupling of proteins/peptides to Eu chelate 
occurs at alkaline pH via reaction of lysine residues and free N termini with the aromatic 
isothiocyanate group of the Europium chelate. To remove compounds interfering with 
labelling, protein and peptides were dialyzed over night. POM antibodies and recPrP were 
diluted in 1 or 0.5 ml 100 mM sodium carbonate (Na2CO3), pH 9-9.3, respectively. Dialysis 
cassettes (Slide-A-Lyzer®, Thermo scientific) were preincubated in ddH2O for 2 min and 
proteins or peptides were loaded with a 24G syringe. In both cases, a dialysis cassette with a 
cut-off of 7 kDa was used, however, for POM antibodies cut-offs of 10-20 kDa are also 
suitable. Dialysis was done under stirring in a volume of 2 l of 100 mM Na2CO3 at 4°C over 
night. Dialysis buffer was changed after 4-6 h of incubation at 4°C. Proteins and peptides 
were concentrated by Centricon concentrators (Millipore). Protein concentration was adjusted 
by the Bradford or BCA assay to a concentration of about 5 mg/ml. Lyophilized Eu-W1024 
ITC chelate (0.1 mg) was stored at –20°C and immediately before use reconstituted in 100 µl 
distilled water which gives a concentration of 1.4 mM. A molar excess of 24x of Europium 
chelate over IgG was added into the protein (peptide) solution on ice and incubated in 100 
mM Na2CO3 over night at 4°C. Separation of the labelled protein from non-reacted chelate 
was performed by size exclusion chromatography (Superdex 200 column, GE Healthcare). 
Elution from column was done with 50 mM Tris-HCl pH 7.8 + 0.9% sodium chloride. Sample 
fractions of 500 µl were collected. Superdex column was decontaminated with 10 mM 
phthalate buffer pH 4.1 containing 0.01% DTPA. Fractions were pooled and concentrated 
with Micron centrifugal filters (Amicon). Labelling ratio and concentration of labelled 
proteins were assessed by a Eu standard solution (Perkin Elmer) and Nano drop measurement, 
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respectively. Aliquots of antibodies were stored at 4°C in the dark. Allophycocyanin (APC, 
AnaTagTM Labeling Kit 72111, Anaspec) was used as acceptor fluorophore for conjugation to 
POM antibodies. Maleimide groups of APC react with sulfhydryl groups on the target 
antibody to form a covalent bond during conjugation. POM antibodies were concentrated to 
2-10 mg/ml in a volume of 100 µl with Centricon concentrators (Millipore). Antibodies were 
reduced with 20 µl dithiothreithol (DTT) per ml of IgG solution for 30 min without agitation 
at room temperature. Depending on reaction volume, reduced antibodies were desalted either 
by spin or gravity columns. Protein concentration was assessed by Nanodrop measurement. 
For the conjugation reaction, 1.5 mg of activated APC per mg reduced IgG was added to the 
reduced antibodies solution and incubated for 1 h at room temperature with agitation. By 
adding DMSO and NEM for 30 min at room temperature, free thiol groups were blocked. To 
remove free APC molecules from antibody solution, reaction mixture was purified via a 
protein G sepharose column (Sigma). The column was washed with water and 10 volumes of 
20 mM phosphate buffer pH 7 to equilibrate. Samples were added and washed with five 
volumes 20 mM phosphate buffer pH 7. Flow through was collected. The column was eluated 
with 0.1 M glycine pH 2.3 and diluted with 1 M TrisHCl pH 8. APC-labelled POM antibodies 
were characterized with Nanodrop (A280 and A650). Aliquots of antibodies were stored at 
4°C in the dark. 
FRET Experiments 
PrPC cell surface FRET labelling: Cells were plated one day before into 96- or 384-well 
microtiter plates (Perkin Elmer) in cell culture medium without phenol red at the desired 
density. Cells were washed once and FRET antibody labelling was performed at 4°C in a total 
volume of 50 µl containing 1 nM Eu-labeled and 5 nM APC-labelled antibodies in 
Tris/KREBS buffer (20 mM Tris pH 7.4, 118 mM NaCl, 5.6 mM glucose, 1.2 mM KH2PO4, 
1.2 mM MgSO4, 4.7 mM KCl, 1.8 mM CaCl2, 1% BSA). FRET signals were measured with 
the Wallac EnVision reader (homogeneous FRET assay). Thereafter, plates were washed with 
Tris/KREBS buffer and the FRET signal was measured again (TR-FRET assay). 
Pharmacological treatment of cells was done with brefeldine A (), diluted in DMSO (), for 18 
h incubation at 37°C. DMSO concentration was kept constant at 0.75%. Cells were washed 
once with ice-cold Tris/KREBS buffer and labelled with FRET antibodies as mentioned 
above. Enymatic treatment of cells was done with PI-PLC. PI-PLC was dialyzed in PBS over 
night and protein concentration was assessed by the Bradford assay (BioRad). Digestion was 
carried out either at 4°C or at 37°C for 1 h during shaking (450 rpm). Supernatant was 
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transferred into a new plate and medium and cells were labelled with FRET antibodies. The 
neuronal Hpl PrP KO cell line [Sakudo A et al., 2007] was used as negative control for assay 
development and optimisation. 
Preparation of Recombinant Mouse mPrP (23-231)  
Recombinant mouse PrP comprising residues 23-231 and the N1 fragment were expressed 
and purified by Simone Hornemann (Zahn et al., 2000; Lysek and Wüthrich, 2004; 
Hornemann et al., 2009). Murine PrP(23-231) fibers were produced by incubating the protein 
at 37 ºC for 48 hours in 50 μM Tris-HCl, 1 M GdnHCl, 150 mM sodium chloride, pH 7.5 and 
shaking at 600 rpm (Apetri et al., 2005). 
siRNA Treatment 
Lyophilyzed human siRNA (Ambion®) was diluted in 500 µl RNase-free water at a stock 
solution of 10 µM and placed on a shaker for 90 min at 37°C. Aliquots were stored at –20°C. 
To transfect siRNA into mammalian cells, LipofectamineTM 2000 (InvitrogenTM) was utilized. 
Briefly, one day before transfection, 2500 cells in 80 µl DMEM cell culture medium without 
antibiotics were seeded into a 96-well plate per well. SiRNA:LipofectamineTM 2000 
complexes were prepared as follows: 5 µl siRNA (1 µM) was diluted in 5 µl prewarmed 
DMEM cell culture medium without serum and antibiotics and mixed gently. 0.1 µl 
LipofectamineTM 2000 was diluted in 9.9 µl prewarmed DMEM cell culture medium without 
serum and antibiotics. After an incubation of 5 min at room temperature, the diluted 
LipofectamineTM 2000 was combined with the diluted siRNA. To allow formation of 
siRNA:LipofectamineTM 2000 complexes, the combined solutions were mixed and incubated 
for 20 min at room temperature. 20 µl of siRNA:LipofectamineTM 2000 complexes were 
added to each well of the 96-well plate and cells were cultured at 37°C in a CO2 incubator for 
72 h. 
Quantitative PCR 
Cell cultures were prepared and incubated as stated above. Cells were washed once with PBS 
and total RNA was extracted using the RNeasy® mini kit (Qiagen) according to the 
manufacturer’s protocol. RNA concentration and purity was determined by Nanodrop 
measurements. cDNA was synthesized from 0.5 µg total RNA with QuantiTect reverse 
transcription kit (Qiagen) using random hexamers according to the manufacturer’s protocol. 
Before cDNA synthesis, genomic DNA was eliminated. Successful cDNA synthesis and 
contamination of total RNA with genomic DNA was tested by PCR with primer specific for 
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GAPDH. Quantitative real-time PCR was performed using the SYBR Green master mix 
(Applied Biosystems) on a ABI Prism VIIA7 sequence detector (PerkinElmer). Fold 
regulation was calculated relative to untreated cells after normalization to the GAPDH signal. 
The following primer pairs were used: VPS28 sense (NM_016208): 5’–TTG TTC CCA GGG 
GCT CCT AT-3’, antisense: 5’–ATC TTC CCG ACC GCG AG-3’. RAB5A sense 
(NM_004162): 5’-TTA GAA AAG CAG CCC CAA TG-3’, antisense 5’-GTA CTT CTG 
GGA GAG TCC GC-3’. AP2M1 sense (NM_004068): 5’-AAT CAT GGC GGC AGA TCA 
GT-3’, sense 5’-ATC TTG GGA TCC GGA GAG TG-3’. GIT2 sense (NM_014776): 5’- 
AGA CAA ATC CAG GCT GCT GT-3’, antisense 5’-GCG CCT CGT GGA AAT ACA GT-
3’. EHD1 sense (NM_006795): 5’-AAG AGC AGG ATG ATG CGG T-3’, antisense 5’-CCT 
GTC TGG AGA GAA GCA GC-3’. M6PR sense (NM_002355): 5’-ATT CTC TCA CTG 
CCA CAG CC-3’, antisense 5’-TGG CTA CTC CAG TTT CCC AC-3’. VPS35 sense 
(NM_018206): 5’-CAC TGA TAG TCT GGT GGG CA-3’, antisense 5’-CAG CTT ACC 
AGC TGG CTT TT-3’. PRNP sense (NM_000311): 5’-AGT GTT CCA TCC TCC AGG C-
3’, antisense 5’-GAG CTT CTC CTC TCC TCA CG-3’. GAPH sense (NM_002046): 5’-CAT 
GAG AAG TAT GAC AAC AGC CT, antisense 5’-AGT CCT TCC ACG ATA CCA AA 
GT-3’. 
Cell Viability Assay 
The alamarBlue® assay (Invitrogen) was utilized to assess cell viability according to the 
manufacturer’s protocol. All experiments were performed in cell culture medium without 
antibiotics and phenol red. Cells were incubated with the alamarBlue dye at 37°C and 
viability was measured after 4-12 hrs. 
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